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1. INTRODUCTION 
1.1 Ovarian cancer 
Among the gynecological malignancies, ovarian cancer is the leading cause of mortality in 
developed countries with 225,500 new cases and 140,200 estimated deaths each year 
worldwide, and its incidence is rising [1]. In Switzerland, statistical data from the Swiss 
Association of Cancer Registries (www.nicer.org) showed that ovarian cancer is the 
seventh most common cancer and the fifth cause of death from cancer in Swiss women [2, 
3]. Ovarian cancer has the highest fatality-to-case ratio of all the gynecologic malignancies, 
primarily because of the difficulty in detecting the disease before widespread 
dissemination [4]. Ovarian cancer are usually asymptomatic until they have metastasized, 
so patients have advanced disease at diagnosis in more than two thirds of the cases with a 
resultant poor prognosis [5]. Even with the use of multimodality approach to treatment, 
including aggressive cytoreductive surgery and combination chemotherapy, the 5-year 
survival rate for carefully and properly staged patients with stage I disease is 76% to 93%, 
depending on the tumor grade. The 5-year survival for stage II is 60% to 74%. The 5-year 
survival rate for stage IIIa is 41%, for stage IIIb about 25%, for stage IIIc 23%, and for 
stage IV disease 11% [5]. Therefore, in clinic ovarian cancer represents a major surgical 
challenge, requires intensive and often complex therapies, and is extremely demanding of 
the patient's psychological and physical energy [5]. 
1.1.1 Risk factors  
The incidence of ovarian cancer increases with age [6] and the peak incidence of invasive 
epithelial ovarian cancer is at 56 to 60 years of age [5]. About 30% of ovarian neoplasms 
in postmenopausal women are malignant, whereas only about 7% of ovarian epithelial 
tumors in premenopausal patients are frankly malignant. The average age of patients with 
borderline tumors is approximately 46 years [5]. The frequency of ovarian cancer varies 
among different geographic regions. The incidence of ovarian cancer in Western European 
countries and in the United States is higher, with a five to sevenfold greater incidence than 
age-matched populations in East Asia. Whites are 50% more likely to develop ovarian 
cancer than blacks living in the United States [4]. A woman's risk at birth of having 
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ovarian cancer sometime in her life is 1% to 1.5%, and that of dying from ovarian cancer 
almost 0.5% [5]. 
Epidemiologic studies have identified risk factors in the etiology of ovarian cancer. 
A 30% to 60% decreased risk of cancer is associated with younger age at pregnancy and 
first birth (25 years or younger), the use of oral contraceptives, and/or breast-feeding [7]. 
Conversely, nulliparity or older age at first birth (older than 35 years) confers an increased 
risk of cancer. Because parity is inversely related to the risk of ovarian cancer, having at 
least one child is protective of the disease, with a risk reduction of 0.3 to 0.4 [5]. Oral 
contraceptive use reduces the risk of epithelial ovarian cancer. Women who use oral 
contraceptives for 5 or more years reduce their relative risk to 0.5 (i.e., there is a 50% 
reduction in the likelihood of development of ovarian cancer) [4, 5]. Additionally, recent 
data suggest that hormone therapy [8] and pelvic inflammatory disease [9] may increase 
the risk for ovarian cancer. The risk of borderline ovarian cancer may be increased after 
ovarian stimulation for in vitro fertilization [10]. 
Most epithelial ovarian cancer is sporadic, with familial or hereditary patterns 
(involving first- or second-degree relatives with a history of epithelial ovarian cancer) 
accounting for 5% to 10% of all malignancies [4, 5]. Having a first-degree relative (i.e., 
mother, sister, daughter) with an epithelial carcinoma gives a 5% lifetime risk for ovarian 
cancer, whereas having two first-degree relatives increases this risk to 20% to 30% [4]. 
Hereditary ovarian cancers in general occur in women approximately 10 years younger 
than those with nonhereditary tumors [4, 5]. Most hereditary ovarian cancer is associated 
with germline mutations in the BRCA1 gene; a small proportion of inherited disease is 
associated with mutations in the gene BRCA2. The mutations are inherited in an autosomal 
dominant fashion, and therefore a full pedigree analysis (i.e., both maternal and paternal 
sides of the family) must be carefully evaluated [5, 11-15]. Additionally, women affected 
with hereditary nonpolyposis colorectal cancer (HNPCC; formerly called Lynch syndrome) 
have approximately a 13-fold greater risk of developing ovarian cancer than the general 
population [4, 12, 16]. In high-risk women (with either BRCA1 or BRCA2 mutations), 
oophorectomy is associated with a reduced risk of ovarian and fallopian tube cancer, 
however, there is a residual risk for primary peritoneal cancer in these high-risk women 
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after prophylactic salpingo-oophorectomy [17-19]. The risk of surgery include injury to the 
bowel, bladder, ureter, and vessels [20]. 
1.1.2 Symptoms and signs 
The majority of women with epithelial ovarian cancer have vague and nonspecific 
symptoms [5]. Symptoms of ovarian cancer are often confused with benign conditions or 
interpreted as part of the aging process, with the final diagnosis often delayed [4]. In early-
stage disease, the patient may experience irregular menses if she is premenopausal. If a 
pelvic mass is compressing the bladder or rectum, she may report urinary frequency or 
constipation [21, 22]. Occasionally, she may perceive lower abdominal distention, pressure, 
or pain, such as dyspareunia. Acute symptoms, such as pain secondary to rupture or torsion, 
are unusual. In advanced-stage disease, patients most often have symptoms related to the 
presence of ascites, omental metastases, or bowel metastases. The symptoms include 
abdominal distention, bloating, constipation, nausea, anorexia, or early satiety [5, 23]. The 
most common symptoms in order from highest percentage to lowest are abdominal fullness 
or distension, abdominal or back pain, decreased energy or lethargy, and urinary frequency, 
especially if these symptoms are new and frequent (> 12 days/month) [4, 24]. 
The most important sign of epithelial ovarian cancer is the presence of a pelvic 
mass on physical examination [5]. Palpation of an asymptomatic adnexal mass during a 
routine pelvic examination is the usual presentation for ovarian cancer. The presence of a 
solid, irregular, fixed pelvic mass on pelvic examination is highly suggestive of an ovarian 
malignancy. The diagnosis of malignancy is almost certain if a fixed, irregular pelvic mass 
is associated with an upper abdominal mass or ascites [5, 23]. 
1.1.3 Diagnosis 
Because of the location of the ovaries and the biology of most epithelial cancers, it has 
been difficult to diagnosis ovarian cancer at an earlier more curable stage [6, 21, 22, 25]. 
The early diagnosis of ovarian cancer is also made even more difficult by the lack of 
effective screening tests [4]. Given the false-positive results for both CA-125 and 
transvaginal ultrasonography, particularly in premenopausal women, these tests are not 
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cost-effective and should not be used routinely to screen for ovarian cancer [5]. 
Furthermore, randomized data do not yet support routine screening for ovarian cancer in 
the general population, and routine screening is not currently recommended by any 
professional society [20, 26, 27]. To date the efficacy of ovarian cancer screening methods 
as tumor markers and ultrasonography remains to be proven [6]. 
CA-125 should not be routinely used to screen for ovarian cancer, but, instead, 
should be used to follow response to therapy and evaluate for recurrent disease [4]. Serum 
CA-125 levels have also been shown to be useful in distinguishing malignant from benign 
pelvic masses [28]. For a postmenopausal patient with an adnexal mass and a very high 
serum CA-125 level (>200 U/mL), there is a 96% positive predictive value for malignancy. 
However, a normal CA-125 measurement alone does not rule out ovarian cancer, because 
up to 50% of early-stage cancers and 20% to 25% of advanced cancers are associated with 
normal values. For premenopausal patients with symptoms, a CA-125 measurement has 
not been shown to be useful in most circumstances and the specificity of the test is low, 
because the CA-125 level tends to be elevated in common benign conditions, including 
uterine leiomyomata, pelvic inflammatory disease, endometriosis, adenomyosis, pregnancy, 
and even menstruation [4, 5]. In the premenopausal patient, a period of observation is 
reasonable, provided the adnexal mass does not have characteristics that suggest 
malignancy (i.e., it is mobile, mostly cystic, unilateral, and of regular contour).  
The diagnosis of an ovarian cancer requires an exploratory laparotomy for 
definitive histologic staging, even though tumor markers (e.g., serum CA-125) and 
ultrasound examination may be helpful in predicting a higher likelihood of a malignant 
tumor than a benign tumor [5]. The threshold for surgical intervention is lower in 
postmenopausal women and those with cysts >3 cm should undergo exploratory surgery, 
laparotomy, or laparoscopy [23]. 
1.1.4 Patterns of spread 
Ovarian epithelial cancers spread primarily by exfoliation of cells into the peritoneal cavity, 
by lymphatic dissemination, and by hematogenous spread (Fig.1). The most common and 
earliest mode of dissemination of ovarian epithelial cancer is by exfoliation of cells that 
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implant along the surfaces of the peritoneal cavity [5]. This process explains widespread 
peritoneal dissemination at the time of diagnosis, even with relatively small primary 
ovarian lesions [4]. Lymphatic dissemination to the pelvic and para-aortic lymph nodes is 
common, particularly in advanced-stage disease [29]. Hematogenous dissemination at the 
time of diagnosis is uncommon [5]. 
 
Fig. 1 Staging ovarian cancer: primary tumor and metastases (FIGO and TNM). 
[Adapted from Heintz, A.P., et al.: Int J Gynaecol Obstet, 2006.] 
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1.1.5 Histologic classification 
The classification of ovarian tumors by cell line of origin is presented in Fig.2 [30]. Both 
benign and malignant tumors can arise from each of the three ovarian cell types [30]: 
• Germ cell tumors include the most common ovarian neoplasm in reproductive-age 
women [4]. In the first two decades of life, almost 70% of ovarian tumors are of germ 
cell origin, and one third of these are malignant [5], which account for 3-5% of ovarian 
cancers [31]. In contrast to the relatively slow-growing epithelial ovarian tumors, germ 
cell malignancies grow rapidly. The most common types of malignant germ cell tumors 
are dysgerminomas, immature teratomas, and endodermal sinus tumors. Preservation of 
fertility should be standard in most patients. The most effective chemotherapy is 
bleomycin, etoposide, and cisplatin (BEP) combination [5]. 
 
Fig. 2   Different ovarian tumors originate from different cell subtypes. Prevalence of malignant  
components in parentheses. [Adapted from Chen, V.W., et al.:Cancer, 2003.] 
 
• Sex-cord-stromal tumors arise from the ovarian connective tissue, often secrete 
hormones, and can occur in women of all ages, comprising approximately 7% of all 
ovarian malignancies [30]. Stromal tumors include granulosa cell tumors, which are 
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low-grade malignancies. In premenopausal women, they can be treated conservatively. 
Adjuvant chemotherapy is of unproven value [5]. 
• Epithelial cell tumors is the largest class of ovarian neoplasm [4]. Approximately 90% 
of ovarian cancers are derived from tissues that come from coelomic epithelium or 
mesothelium [23] and more than 80% of epithelial ovarian cancers are found in 
postmenopausal women [5]. The types of epithelial tumors classified are as follows: 
serous, mucinous, endometrioid, clear cell (mesonephroid), Brenner, mixed epithelial, 
undifferentiated and unclassified [5]. Seventy-five percent of epithelial cancers are of 
the serous histologic type. Less common types are mucinous (20%), endometrioid (2%), 
clear cell, Brenner, and undifferentiated carcinomas, and each of the last three types 
represents less than 1% of epithelial lesions [5]. 
In addition to benign and malignant epithelial lesions, borderline tumors of low-
malignant potential contain morphologically and molecularly partially transformed 
epithelial cells that do not invade underlying stroma [30]. These tumors generally remain 
confined to the ovary, are more common in premenopausal women (30 to 50 years of age), 
and have good prognoses [32]. About 20% of such tumors show spread beyond the ovary. 
They require carefully individualized therapy following the initial surgical resection of the 
primary tumor. If frozen section pathology demonstrates borderline histology, unilateral 
oophorectomy with a staging procedure and follow up is appropriate, assuming the woman 
wishes to retain ovarian function and/or fertility and understands the risks of such 
conservative management [4]. Approximately 10% of borderline tumors can recur after 
resection and prove lethal [30]. 
1.1.6 Staging 
The staging of ovarian carcinoma is based on extent of spread of tumor and histologic 
evaluation of the tumor [4]. Ovarian malignancies are surgically staged according to the 
2002 revised American Joint Committee on Cancer (AJCC) and International Federation of 
Gynaecology and Obstetrics (FIGO) joint staging system, which is presented in Table 1 
and Table 2 [6, 33]. Clinical and radiological evaluation may affect the final staging. 
Histopathological typing is to be considered at staging [5, 23]. 
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Table 1 Carcinoma of the ovary: FIGO nomenclature (Rio de Janeiro 1988) [Adapted from Heintz, A.P., et 
al.: Int J Gynaecol Obstet, 2006.] 
 
 
Histopathologic grade (G) 
• GX: Grade cannot be assessed 
• G1: Well differentiated 
• G2: Moderately differentiated 
• G3: Poorly or undifferentiated 
 
Table 2 Carcinoma of the ovary: Stage grouping for ovarian cancer 
          [Adapted from Heintz, A.P., et al.: Int J Gynaecol Obstet, 2006.] 
 
 
FIGO 
 
UICC 
 T N M 
Ia T1a N0 M0 
Ib T1b N0 M0 
Ic T1c N0 M0 
IIa T2a N0 M0 
IIb T2b N0 M0 
IIc T2c N0 M0 
IIIa T3a N0 M0 
IIIb T3b N0 M0 
IIIc T3c N0 M0 
 any T N1 M0 
IV any T any N M1 
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1.2 Ovarian cancer and treatments 
Primary treatment for presumed ovarian cancer consists of appropriate surgical staging and 
cytoreduction, followed in most (but not all) patients by systemic chemotherapy [6]. Over 
the last three decades, 5-year survival for ovarian cancer patients has increased from 37 to 
45%, related to more consistent use of cytoreductive surgery and combination 
chemotherapy with platinum compounds and taxanes [34]. However, ovarian cancer still 
ranks as the most deadly gynecologic cancer and less than 40% of all stages can be cured 
[30, 35]. Currently, emerging treatment strategies have focused on targets which are 
integral to tumor growth and metastasis, and some innovative agents are being developed 
and under investigation in clinical trials [35].  
1.2.1 Surgical management 
Surgery is necessary for diagnosis, accurate staging and optimal cytoreduction, and is 
crucial for the successful treatment of ovarian cancer [23]. The importance of thorough 
surgical staging cannot be overemphasized, because subsequent treatment will be 
determined by the stage of disease [5]. 
Primary surgical therapy is indicated in most of the ovarian malignancies, using the 
principle of cytoreductive surgery, or “tumor debulking”. The rationale for cytoreductive 
surgery is that adjunctive radiation therapy and chemotherapy are more effective when all 
tumor masses are reduced to less than 1 cm in size [4]. Because direct peritoneal seeding is 
the primary method of intraperitoneal spread, multiple adjacent structures commonly 
contain tumor, resulting in cytoreductive procedures that are often extensive [4]. Patients 
with advanced-stage disease should undergo “debulking” or cytoreductive surgery to 
remove as much of the tumor and its metastases as possible, if the patient is medically 
stable. A thorough abdominal exploration, total abdominal hysterectomy, bilateral 
salpingo-oophorectomy, lymphadenectomy, omentectomy, and removal of all gross cancer 
are standard therapy for malignant ovarian tumor. The performance of a debulking 
operation as early as possible in the course of the patient's treatment should be considered 
the standard of care [5, 36]. Surgery can be performed after neoadjuvant chemotherapy 
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[37], when optimal cytoreduction is not considered feasible at initial diagnosis. Survival 
increases with the expertise of the surgeon [38], and optimal cytoreductive surgery is an 
independent prognostic factor [39]. 
In several retrospective series, cytoreductive surgery for recurrent disease has been 
associated with improved survival when all macroscopic cancer can be removed [40, 41]. 
Two ongoing prospective trials in Europe and the United States are evaluating criteria and 
outcomes for secondary cytoreduction [30]. 
1.2.2 Adjuvant therapy 
1.2.2.1 Chemotherapy 
Because most ovarian cancer presents at an advanced stage, adjunctive treatment using 
systemic chemotherapy is usually necessary. However, patients with stage IA or IB disease 
(who have been completely surgically staged) and who have borderline, well- or 
moderately differentiated tumors do not benefit from additional chemotherapy because 
their prognosis is excellent with surgery alone [6, 23, 42].  
Chemotherapy improves survival and is an effective means of palliation of ovarian 
cancer. In patients who are at increased risk of recurrence (stage I G3 and all IC-IV), 
chemotherapy is recommended. Sequential clinical trials of chemotherapy agents 
demonstrate that cisplatin (or carboplatin) given in combination with paclitaxel is the most 
active combination identified [23]. Carboplatin is an alkylating agent that binds covalently 
to DNA, creating adducts that form intrachain and interchain cross-links. Paclitaxel binds 
noncovalently to microtubules and increases their stability, interfering with mitotic spindle 
formation. Both agents induce apoptosis. Chemotherapy has generally been administered 
intravenously, but three randomized phase III trials have shown a 20-25% relative risk 
reduction in mortality after intraperitoneal therapy for patients who have been optimally 
cytoreduced [43-45]. For advanced stage epithelial ovarian cancer, the choice of 
intravenous versus intraperitoneal platinum and taxane chemotherapy should be 
individualized [5]. 
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Six cycles of carboplatin and paclitaxel chemotherapy are considered standard 
adjuvant treatment for newly diagnosed ovarian cancer after cytoreductive surgery [30]. 
Recommendations for the number of cycles of treatment also can vary with the stage of the 
disease. For patients with advanced-stage disease (stages II-IV), 6-8 cycles of 
chemotherapy are recommended, whereas 3 to 6 cycles are recommended for earlier-stage 
disease [46]. Chemotherapy is generally administered every 3 weeks, but weekly dose-
dense administration of paclitaxel has produced improved survival in one trial from Japan 
[47], and a confirmatory trial has not yet been completed. 
More than 70% of patients with advanced ovarian cancer will experience disease 
recurrence and become candidates for second-line chemotherapy, within 12 and 18 months. 
Retreatment with carboplatin and paclitaxel is associated with a 20-50% response when 
platinum-sensitive disease recurs more than 6 months after primary chemotherapy [30]. 
Although recurrent disease is not curable, combinations of drugs can prolong survival. 
Disease that recurs in less than 6 months is considered platinum resistant. In this setting, 
several drugs produce response rates ranging from 10-30% and increase progression-free 
survival such as liposomal doxorubicin, weekly paclitaxel, and topotecan. Other drugs 
have demonstrated activity in phase II clinical studies, including gemcitabine, 
bevacizumab, docetaxel, and etoposide [6, 30]. 
1.2.2.2 Radiation therapy 
Radiation therapy has only a limited role in the management of ovarian cancer [4]. Whole-
abdominal radiation therapy (WART) given as a salvage treatment has been shown to be 
associated with a relatively high morbidity [5], so WART in patients with low-bulk stage 
III disease is no longer included as an option for initial treatment or consolidation 
treatment in ovarian cancer [6]. Palliative localized radiation therapy is an option for 
symptom control in patients with recurrent disease. Patients who receive radiation are 
prone to vaginal stenosis, which can impair sexual function. Women can use vaginal 
dilators to prevent or treat vaginal stenosis [48, 49]. 
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1.2.3 Novel therapeutic strategies 
The next horizon for ovarian cancer treatment is molecularly targeted agents, 
immunotherapy, and gene therapy [4].  
1.2.3.1 Molecularly targeted agents  
Emerging treatment strategies have focused on targets which are integral to tumor growth 
and metastasis. Targeted molecular strategies have been employed in the treatment of 
ovarian cancer. These strategies attempt to manipulate processes critical to ovarian 
carcinogenesis, including cellular growth and proliferation, cellular adhesion, intracellular 
signaling pathways, angiogenesis, and DNA repair pathways [35, 50].  
Several kind of agents are currently available that target specific molecules or 
proteins in ovarian cancer cells. For example, angiogenesis is critical to tumor 
growth/metastasis and several proangiogenic factors, including vascular endothelial growth 
factor (VEGF), IL-8, platelet-derived endothelial cell growth factor (PDGF), angiogenin, 
and fibroblast growth factor (FGF), have been implicated in tumorigenesis [51]. Inhibitors 
of proangiogenic proteins such as VEGF (bevacizumab and aflibercept), angiopoietins 
(AMG386), PDGF (imatinib and pazopanib), or their receptors VEGF receptor (pazopanib, 
sorafenib, sunitinib, and BIBF1120) are being tested for possible treatment of EOC in the 
clinic [30]. Of these targeted molecules, VEGF has been the most commonly studied, 
given that it is abundantly present in the serum of patients with EOC [52, 53], and that 
elevated VEGF levels have been associated with poor survival [54]. Bevacizumab is a 
monoclonal antibody designed to target the VEGF protein and inhibit angiogenesis in 
tumors. Two recent trials have added a VEGF-binding antiangiogenic antibody, 
bevacizumab, to standard treatment during and for up to 15 months after chemotherapy. 
Improved progression-free but not overall survival was reported [55, 56]. According to the 
data from GOG 0218 and ICON7, recently the National Comprehensive Cancer Network 
(NCCN) Ovarian Cancer panel does not recommend the routine addition of bevacizumab 
to upfront therapy with carboplatin/paclitaxel or as maintenance therapy at this time. The 
NCCN panel encourages participation in ongoing clinical trials that are further 
investigating the role of anti-angiogenesis agents in the treatment of ovarian cancer, both in 
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the upfront and recurrence settings [6]. Additionally, trastuzumab is a DNA-derived 
monoclonal antibody to the HER2, a member of the epidermal growth factor receptor 
(EGFR/ErbB) family. Treatment with trastuzumab is currently indicated in patients with 
metastatic breast cancer whose tumors overexpress HER2 [57]. Some ovarian cancers 
express the HER2/neu receptor [58]; therefore, investigation is currently ongoing regarding 
the usefulness of this agent in ovarian cancer. Preliminary results from a phase II GOG 
trial suggested that the overall potential therapeutic benefit for trastuzumab in EOC might 
be limited [59]. Furthermore, one of the best examples of synthetic lethality to reach the 
clinic to date is provided by the activity of poly-ADP ribose polymerase (PARP) inhibitors 
in ovarian cancers that display BRCAness, i.e. a deficiency of BRCA1/2 function [60, 61] 
is associated with a better overall prognosis [62] and response to platinum compounds [63]. 
BRCA1 and BRCA2 mediate homologous recombination, which is one mechanism of 
DNA repair [64]. Cancers with BRCAness are deficient in homologous repair and cannot 
repair DNA double strand breaks induced by platinum compounds [65]. Inhibition of a 
second DNA repair pathway, base excision repair, by PARP inhibitors causes synthetic 
lethality in cancers with BRCAness [66]. Olaparib is the most studied PARP inhibitor in 
women with EOC. The results from clinical trials showed that olaparib might be an 
efficacious and safe treatment option in BRCA-mutated advanced ovarian cancer [67, 68]. 
In addition to targeted agents above-mentioned, other innovative agents targeting cellular 
adhesion molecules (such as Catumaxomab) [69] and folate metabolism (such as anti-
human folate receptor-alpha monoclonal antibodies) [70, 71] currently are also under 
investigation in clinical trials.  
1.2.3.2 Immunotherapy 
Effective host anti-tumor immune responses have the potential to influence prognosis in 
patients with EOC. By manipulating the host immune system, it may be possible to 
enhance host antitumor immune responses and improve patient outcomes. Current 
immunotherapeutic approaches employ vaccines based on tumor-associated antigens 
(TAA), DC-based immunotherapy, adoptive immunity, antitumor cytokines or antibodies 
targeting co-stimulatory and immunosuppressive molecules [72]. 
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Tumor vaccines are currently being investigated for the treatment of ovarian cancer. 
Several proteins that are abnormally expressed in cancer cells, due to mutations, 
overexpression, or post-translational modifications, have been identified and are currently 
studied as targets for immunotherapy. In a recent analysis from the National Cancer 
Institute Pilot Project for the acceleration of translational research, 75 tumor antigens were 
priority ranked for cancer vaccine development [73]. Some of these antigens, including 
MUC1, CA-125, human epidermal growth factor receptor 2 (HER2)/neu, membrane folate 
receptor, TAG-72, mesothelin, and NY-ESO-1, are targets of therapeutic tumor vaccines in 
ovarian cancer [72]. Additionally, vaccine-approaches in EOC have also utilized whole 
tumor cell lysates and dendritic cells (DCs) in an attempt to boost host anti-tumor immune 
responses. The former affords the opportunity for broad tumor antigen exposure, while use 
of dendritic cells enhances anti-tumor immunity via specific tumor-antigen presentation 
and activation of effector T cells [50]. Adoptive immunity is a process by which immune 
cells, including T lymphocytes, B lymphocytes, natural killer cells, and macrophages, are 
removed from an individual, modified extracorporeally and then placed back into the same 
individual [74]. The adoptive transfer of autologous tumor-infiltrating lymphocytes (TILs) 
has proven to be high response rates in a sample of women with advanced or recurrent 
EOC [75], and subsequent studies in ovarian cancer have examined the utility of adoptive 
transfer with modified T cells to enhance antitumor activity [76]. Proinflammatory 
cytokines, including interleukins (IL) 2, 4, 7, 12 and 18, interferon gamma (IFN-γ), tumor 
necrosis factor alpha (TNF-α), and granulocyte-macrophage colony-stimulating factor 
(GM-CSF), have been utilized in preclinical models to induce anti-tumor immune 
responses [35]. In addition, investigations have begun focusing on molecules (e.g., 
cytotoxic T lymphocyte-associated antigen 4, CTLA-4) [77] and cell populations 
(regulatory T cells, Tregs) [78] which suppress host immune responses. These trials will 
hopefully reinforce the utility of these novel immunotherapeutic techniques in the 
treatment of recurrent EOC. Currently the response to this type of therapy has been modest, 
but studies are ongoing. 
1.2.3.3 Gene therapy 
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Because some ovarian cancers result from loss of genetic function through DNA mutations, 
investigational therapies have also focused on genetic manipulation of the tumors, or gene 
therapy. For instance, because half of ovarian cancers exhibit deleterious mutations in the 
p53 gene, research has focused on delivering a normal p53 gene product to the tumor using 
a variety of viral vectors. The hope is that the wild-type gene product would then be 
expressed by the tumor and the growth would then be inhibited. So far, response has been 
minimal, but investigation continues [4]. 
The potential benefits of these novel therapeutic concepts are manifold, whether 
considered as primary or adjunct therapy. Work in this area is in the experimental stage or 
under investigation in clinical trials, but the goal of eliminating cancer cells with minimal 
toxicity remains the goal of cancer therapeutics [4]. 
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1.3 Cisplatin-resistance in ovarian cancer 
Cisplatin is one of the most potent antitumor agents known, displaying clinical activity 
against a wide variety of solid tumors, including ovarian cancer [79, 80]. Cisplatin often 
leads to an initial therapeutic success associated with partial responses or disease 
stabilization in ovarian cancer. Unfortunately, the initial response rate of up to 70% is not 
durable, and results in a 5-year patient survival rate of only 30% in patients with advanced 
ovarian cancer, primarily as originally sensitive tumors eventually develop 
chemoresistance, leading to therapeutic failure [81-84]. The onset of resistance creates a 
further therapeutic complication in that tumors failing to respond to cisplatin are cross-
resistant to diverse unrelated drugs; therefore, the benefits of second-line chemotherapy 
diminish substantially, and eventually patients succumb to their disease [79]. In addition, 
the cytotoxicity of cisplatin (which is given intravenously as short-term infusion in 
physiological saline) also affects kidneys (nephrotoxicity), peripheral nerves (neurotoxicity) 
and the inner ear (ototoxicity) [85, 86]. Still, the main limitation to the clinical usefulness 
of cisplatin as an anticancer drug is the high incidence of chemoresistance [87]. 
1.3.1 Cisplatin and mode of action 
The therapeutic activity of cisplatin is mediated by an active species, formed by aqueous 
hydrolysis as the drug enters the cell. This active species interacts with DNA, RNA and 
protein, but the cytotoxic effect seems to be primarily mediated via the formation of DNA 
interstrand and intrastrand crosslinks [79]. These platinum-DNA adducts are recognized by 
a number of proteins, including those involved in nucleotide excision repair (NER), 
mismatch repair (MMR), and high-mobility-group proteins (such as HMG1 and HMG2) 
[88, 89]. Platinum-induced DNA damage is normally repaired by the NER pathway [90-
93]. However, proteins belonging to MMR system also participate in the recognition and 
resolution of cisplatin lesions [94]. When the extent of damage is limited, cisplatin adducts 
induce an arrest in the S and G2 phases of the cell cycle, a phenomenon that exerts 
cytoprotective effects by (1) allowing repair mechanisms to re-establish DNA integrity and 
(2) preventing potentially abortive or abnormal mitoses [95]. Conversely, if DNA damage 
is beyond repair, cells become committed to (most often apoptotic) death. 
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Cisplatin exerts anticancer effects via multiple mechanisms, yet its most prominent 
(and best understood) mode of action involves the generation of DNA lesions followed by 
the activation of the DNA damage response (DDR) and the induction of mitochondrial 
apoptosis [87]. The pathways involved in cisplatin-induced cytotoxicity are summarized in 
Fig.3.  
 
Fig.3 An overview of pathways involved in mediating cisplatin-induced cellular effects.  
 [Adapted from Siddik, Z.H., et al.:Oncogene, 2003.] 
 
Aquated cisplatin can indeed bind a plethora of nucleophilic species, including 
cysteine and methionine residues on proteins and DNA bases. In the nucleus, this leads to 
the generation of inter- and intra-strand adducts that are recognized by the DNA damage-
sensing machinery. If the extent of damage is beyond repair, cisplatin adducts trigger the 
activation of a DNA damage response that frequently involves the ATR kinase, CHEK1, 
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CHEK2, p73, MAPK and the tumor suppressor protein TP53. In turn, TP53 transactivates 
several genes whose products facilitate mitochondrial outer membrane permeabilization 
(MOMP), thereby triggering intrinsic apoptosis, as well as genes that encode for 
components of the extrinsic apoptotic pathway. MOMP sets off the caspase cascade as well 
as multiple caspase-independent mechanisms that eventually seal the cell fate. In the 
cytoplasm, the interaction between cisplatin and glutathione (GSH), metallothioneins or 
mitochondrial proteins like the voltage-dependent anion channel (VDAC) results in the 
depletion of reducing equivalents and/or directly sustains the generation of reactive oxygen 
species (ROS). ROS can directly trigger MOMP or exacerbate cisplatin-induced DNA 
damage, thereby playing a dual role in cisplatin cytotoxicity [87]. 
The cisplatin-resistant phenotype of cancer cells can derive from alterations in any 
of these molecular circuitries as well as from changes that affect the intracellular uptake of 
cisplatin or the execution of the apoptotic program. 
1.3.2 Mechanism of cisplatin resistance 
Drug resistance is thought to cause treatment failure and death in more than 90% of 
patients with metastatic disease. Reasons for the clinical failure of chemotherapy and 
‘apparent drug resistance’ can be classified into three broad categories: pharmacokinetic, 
tumour micro-environmental and cancer-cell specific [81]. Pharmacokinetic resistance is 
caused by inadequate tumour-cell drug exposure due to interpatient differences in 
pharmacokinetic variables [96]. The tumour microenvironment can also modulate tumour-
cell drug sensitivity. For example, hypoxia has long been known to induce radioresistance, 
and is now also implicated in chemoresistance [97]. Historically, the main research 
emphasis has been on tumour-cell-specific mechanisms of drug resistance and, in 
particular, on those that influence drug-target interactions and subsequent cell damage. 
Still, in ovarian cancer it seems likely that two parallel phenomena underlie clinical drug 
resistance [98, 99], and this is illustrated in Fig.4.  
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Fig.4 Models of treatment failure in ovarian cancer. CTX, chemotherapy. Chemosensitive cells, blue; stem 
cells that are drug insensitive due to relative quiescence, yellow; resistant cells due to somatic 
mutation, brown. [Adapted from Agarwal, R., et al.:Nature Reviews Cancer, 2003.] 
 
a) The somatic mutation model of relapse proposes growth of resistant tumour-cell clones 
that remain at the end of chemotherapy, and provides the rationale for combination and/or 
sequential chemotherapy. However, it is important to consider that cytotoxic agents are 
primarily effective against proliferating cells and that, even in rapidly proliferating 
tumours, a significant proportion of cancer cells are in a quiescent state. These quiescent 
cells therefore show a degree of drug resistance relative to cycling cells [99].  
b) Recent studies have shown that a number of proteins that are involved in cell-cycle 
regulation (such as MYC, RB, INK4A, cyclin-A-CDK2, E1A and E2F1) also interact with 
apoptotic pathways and cell death in response to chemotherapeutic agents and provide the 
molecular link between the degree of cell proliferation and intrinsic chemosensitivity 
[100]. Subsequent relapse is then due to the re-growth of persistent stem cells that were 
predominantly in G0. This model goes some way to explaining the observation that 
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patients who relapse after initial chemotherapy can often be retreated with the same agents 
and achieve complete clinical responses. 
c) In practice, chemoresistance develops despite initial chemosensitive relapses, and it 
therefore seems likely that both models presented in a and b underlie clinical drug 
resistance in ovarian cancer. These two processes presumably occur concurrently, but the 
relative proportions vary from individual to individual, and determine the clinical pattern 
of relapse and drug sensitivity. 
The three reasons above-mentioned influence the response to chemotherapy by 
principally affecting intracellular active drug concentrations, drug-target interactions, 
target-mediated cell damage, damage-induced apoptotic signalling or the apoptotic effector 
machinery [81]. During the past 30 years an intense research has been conducted and 
several mechanisms that account for the cisplatin-resistant phenotype of tumor cells have 
been described. These mechanisms can be systematically classified in alterations (1) that 
involve steps preceding the binding of cisplatin to DNA (pre-target resistance), (2) that 
directly relate to DNA-cisplatin adducts (on-target resistance), (3) concerning the lethal 
signaling pathway(s) elicited by cisplatin-mediated DNA damage (post-target resistance) 
and (4) affecting molecular circuitries that do not present obvious links with cisplatin-
elicited signals (off-target resistance) [87].  
1.3.2.1 Mechanisms of pre-target resistance 
There are at least two mechanisms by which cancer cells elude the cytotoxic potential of 
cisplatin before it binds to cytoplasmic targets and DNA: (1) a reduced intracellular 
accumulation of cisplatin, including reduced uptake of cisplatin, such as downregulated 
copper transporter 1 (CTR1) in cisplatin-resistant cancer cells [101, 102], and increased 
efflux of cisplatin, such as upregulated ATP7A/ATP7B [103, 104] or multidrug-resistance 
protein 2 (MRP2) in cisplatin-resistant cancer cells [105-107]. (2) An increased 
sequestration of cisplatin by GSH, metallothioneins and other cytoplasmic ‘scavengers’ 
with nucleophilic properties [108]. This process is catalysed intracellularly by a family of 
glutathione-S-transferase (GST) enzymes, but studies correlating response and prognosis 
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following platinum-based chemotherapy and GST expression in ovarian cancer have 
yielded contradictory results [109, 110]. 
1.3.2.2 Mechanisms of on-target resistance 
The recognition of inter- and intra-strand DNA adducts and the consequent generation of 
an apoptotic signal is often impaired in cisplatin-resistant cancer cells because of a variety 
of defects. Alternatively, cisplatin-resistant cells acquire the ability to repair adducts at an 
increased pace, or become able to tolerate unrepaired DNA lesions [87]. As discussed 
previously, cisplatin induces apoptosis by forming DNA-platinum adducts. DNA adducts 
can be removed and the DNA repaired via the NER pathway [90]. In this setting, damaged 
nucleotides are excised from DNA upon incision on both sides of the lesion, followed by 
DNA synthesis to reconstitute genetic integrity [111]. At least 20 proteins participate in 
NER, including excision repair cross-complementing rodent repair deficiency, 
complementation group 1 (ERCC1). ERCC1 expression has been negatively correlated 
with survival and/or responsiveness to cisplatin-based regimens in several human 
neoplasms including ovarian cancer [112]. An alternative mechanism of DNA repair is via 
MMR, which normally handles erroneous insertions, deletions and mis-incorporations of 
bases that can arise during DNA replication and recombination [94, 113]. MMR-related 
proteins that participate in the recognition of GpG interstrand adducts include MSH2 and 
MLH1 [113, 114]. According to accepted viewpoints, MMR proteins would attempt to 
repair cisplatin adducts, fail, and hence transmit a proapoptotic signal [113]. MLH1 is 
silenced by methylation in a significant proportion of ovarian tumours, and this correlates 
with cisplatin resistance in some patients [115]. The methylation-dependent silencing of 
MLH1 has also been shown to predict poor survival in ovarian cancer patients [116]. In 
addition, cisplatin-induced inter-strand adducts can lead to the so-called double-strand 
breaks, DNA lesions that are normally repaired in the S phase of the cell cycle (or shortly 
after) by the machinery for homologous recombination (HR) [117]. Two critical 
components of the HR system are encoded by BRCA1 and BRCA2, two genes that are 
frequently mutated in familial breast and ovarian cancers [118, 119]. Notably, HR-
deficient cancers have a different phenotype and are often more sensitive to crosslinking 
agents including cisplatin than their HR-proficient counterparts [120-122]. These 
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observations suggest that the HR status, at least in specific clinical settings, has an 
important prognostic and predictive value. 
1.3.2.3 Mechanisms of post-target resistance 
Post-target resistance to cisplatin can result from a plethora of alterations including defects 
in the signal transduction pathways that normally elicit apoptosis in response to DNA 
damage as well as problems with the cell death executioner machinery itself [87]. Because 
most tumours develop a broad cross-resistance to the different chemotherapeutic agents 
and radiotherapy that they encounter during treatment, recently research emphasis shifts 
away from drug-specific mechanisms of resistance to defects in the common apoptotic 
signalling and effector pathways downstream of drug-target interactions, as the probable 
causes of resistance in clinical practice [81]. A number of proteins involved in these 
pathways are oncogenes (such as RAS and AKT) and tumour-suppressor genes (such as 
TP53 and PTEN), whereas others are components of the apoptotic machinery (such as 
survivin, XIAP and the BCL2 family). One model of cisplatin-mediated cytotoxicity is 
based on the recognition of DNA damage by MMR proteins and activation of p53. The 
activation of p53, in turn, leads to transcriptional upregulation of pro-apoptotic proteins 
such as BAX, BAK, CD95 and TRAIL (TNF-related apoptosis-inducing ligand), and 
downregulation of anti-apoptotic proteins such as BCL2, BCL-XL and IAPs, resulting in 
cell death via apoptosis [123]. Inactivation of p53 could therefore result in drug resistance. 
This hypothesis is supported by in vitro data in some cell lines [124]. The role of p53 has 
been extensively evaluated in clinical studies that correlate p53 status with response to 
chemotherapy and overall survival [125]. In addition, the threshold for apoptosis in 
response to chemotherapy-induced cellular damage is modulated by signalling through the 
PI3K, MAPK and protein kinase C (PKC) pathways [126]. In cell lines, activation of the 
PI3K pathway has been shown to correlate with resistance to cisplatin [127]. 
Amplifications of PI3K and activation of AKT have been found in 30-40% of ovarian 
tumours in some studies, and represent potential mechanisms of drug resistance in clinical 
practice [128]. Preclinical studies suggest that other proapoptotic signal transducers such as 
MAPK family members might also contribute to the cisplatin-resistant phenotype in 
ovarian cancer [129, 130]. In particular, it has been proposed that cisplatin-resistant cells 
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would fail to activate MAPK1 (also known as p38 MAPK) and c-JUN N-terminal kinase in 
a sustained fashion in response to cisplatin [129, 131]. Contrarily to the case of TP53, so 
far no correlation has been found between the levels of MAPKs or MAPK-related proteins 
and cisplatin sensitivity in patients [87]. Furthermore, Alterations in any of the factors that 
regulate and execute apoptosis, be it triggered by DNA damage or oxidative stress via the 
mitochondrial pathway or be it mediated by the extrinsic route, have the potential to 
influence cisplatin sensitivity [87]. In ovarian cancer, the upregulation of anti-apoptotic 
proteins such as BCL2, IAPs and the heat-shock proteins (HSP70 and HSP90), and 
downregulation of pro-apoptotic proteins such as BAX, have been shown to affect cisplatin 
sensitivity in vitro. The role of BCL2 and the IAP survivin in mediating cisplatin resistance 
is also supported by clinical studies [132, 133]. The inhibitors of survivin or BCL2 are 
currently being evaluated as single agents or in combination with cisplatin for the 
treatment of ovarian cancer [134, 135]. 
1.3.2.4 Mechanisms of off-target resistance 
Accumulating evidence suggests that the cisplatin resistant phenotype can also be 
sustained (if not entirely generated) by alterations in signaling pathways that are not 
directly engaged by cisplatin, yet compensate for (and hence interrupt) cisplatin-induced 
lethal signals. The ERBB2 protooncogene (also known as HER2 or NEU), which codes for 
a member of the epidermal growth factor receptor family of tyrosine kinases, is 
overexpressed in ovarian cancers [136] and can signal via both the MAPK and PI3K 
pathways [137]. Activation of these pathways leads to phosphorylation of AKT and 
MAPK, which, in turn, phosphorylate BAD and BCL2 and inhibit apoptosis. In vitro 
overexpression of these receptors is associated with activation of the signalling pathways 
and resistance to cisplatin chemotherapy [138, 139]. In some clinical studies, there seems 
to be a correlation between overexpression of ERBB2 and poor prognosis in ovarian 
cancer [136]. Other general stress response pathways or poorly characterized mechanisms 
have been linked to cisplatin resistance in ovarian cancer include autophagy and dual-
specificity Y-phosphorylation regulated kinase 1B (DYRK1B, also known as MIRK). 
Autophagy is an evolutionary conserved catabolic pathway that involves the sequestration 
and lysosomal degradation of organelles and portions of the cytoplasm [140]. Ovarian 
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cancer cells have been shown to progressively acquire cisplatin resistance while 
upregulating components of the autophagic pathway [141, 142]. DYRK1B is upregulated 
in multiple solid tumors [143] and exerts prosurvival functions by increasing the 
expression of antioxidant enzymes such as ferroxidase, superoxide dismutase 2 and 
superoxide dismutase 3 [144]. In ovarian cancer cells, DYRK1B depletion has been shown 
to potentiate the effects of subapoptotic cisplatin concentrations by favoring the 
establishment of lethal oxidative stress [145, 146]. 
Cisplatin is an important therapeutic tool in the combat against ovarian cancer. 
Unfortunately, cancer cells either intrinsically are or relatively rapidly become resistant to 
cisplatin, leading to relapse and therapeutic failure. The mechanisms responsible for 
cisplatin resistance are several, and contribute to the multifactorial nature of the problem. 
The elucidation of the mechanisms by which tumors become refractory to cisplatin will 
lead not only to optimal chemosensitization strategies, but also to the discovery of new 
prognostic and predictive biomarkers.  
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1.4 Salinomycin and cancers 
Salinomycin (Sal) is a monocarboxylic polyether ionophore isolated from Streptomyces 
albus and has been shown to exhibit antimicrobial activity against gram-positive bacteria 
including mycobacteria and Staphylococcus aureus, some filamentous fungi, Plasmodium 
falciparum, and Eimeria spp., protozoan parasites responsible for the poultry disease 
coccidiosis [147-149]. Thus salinomycin has been used for more than 30 years as an 
effective anticoccidial drug in poultry [150] and is also fed to ruminants and pigs to 
improve nutrient absorption and feed efficiency [151-153]. Very recently, salinomycin has 
been shown to kill human cancer stem cells and to inhibit breast cancer growth and 
metastasis in mice [154]. Salinomycin is also able to induce massive apoptosis in human 
cancer cells of different origins that display multiple mechanisms of drug and apoptosis 
resistance [155]. Therefore, at present salinomycin is considered to be a potential 
anticancer drug for cancer chemoprevention and cancer therapy. 
1.4.1 Structure of salinomycin 
In 1974, a new biologically active substance from the culture broth of Streptomyces albus 
(strain No. 80614) was isolated and termed salinomycin [148]. Salinomycin is a 751 Da 
monocarboxylic polyether antibiotic that constitutes a large pentacyclic molecule with a 
unique tricyclic spiroketal ring system and an unsaturated six-membered ring (Fig.5). It is 
a lipophilic, anionic and weakly acidic compound with the molecular formula C42H70O11 
[148, 156].  
 
 
Fig.5 Structural formula of salinomycin. The pentacyclic molecule with a unique 
tricyclic spiroketal ring system has a mass of 751 Da, a molecular formula 
of C42H70O11, a melting point of 113˚C and a UV absortion at 285 nm. 
[Adapted from Miyazaki, Y., et al.: J Antibiot, 1974.] 
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 Salinomycin and its salts exist in a pseudo-cyclic structure because of the 
formation of hydrogen bonds between the carboxylic group on the one side of the molecule 
and two hydroxyl groups on the opposite side (Fig.6) [157]. Owing to its lipophilic surface, 
polar inner core containing oxygen atoms and one carboxylic group, it is well suited for 
transporting monovalent cations, especially H+, Na+ and great preference for potassium K+ 
across lipid cytoplasmic and mitochondrial membranes [157]. The mechanism by which 
salinomycin interacts with coccidia and rumen microflora is well known. The normal 
physiological steady state of most living cells is dependent on the establishment of 
intracellular and extracellular level of Na+ and K+. Intracellular concentration of K+ is 
higher than that of Na+, and extracellular concentrations are respectively reversed. 
Salinomycin as a polyether ionophore can easily penetrate cellular membranes owing to its 
lipophilic properties and disrupt the Na+/K+ ion balance across cell membranes, which 
finally leads to the cell death [157]. 
 
Fig.6 Structure of salinomycin sodium salt complex. 
  [Adapted from Huczynski, A.: Chem Biol Drug Des, 2012.] 
 
1.4.2 Anticancer action of salinomycin 
Cancer stem cells (CSCs) have been defined as cells within tumor that possess the capacity 
to self-renew and to cause the heterogeneous lineages of cancer cells that comprise the 
tumor [158-160]. Cancer stem cells have been identified in a variety of human neoplasias, 
including cancers of the blood, breast, brain, bone, skin, liver, bladder, ovary, prostate, 
colon, pancreas and so on [161, 162]. It is often considered to be associated with chemo-
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resistance and radio-resistance that lead to the failure of traditional therapies. Most 
therapies are directed at the fast growing tumor mass but not the slow dividing cancer stem 
cells. Eradicating cancer stem cells, the root of cancer origin and recurrence, has been 
thought as a promising approach to improve cancer survival or even to cure cancer patients 
[158].  
In 2009, Gupta et al. [154] announced in the journal Cell that salinomycin, one of 
the antibiotics currently used in veterinary medicine, is a 100 times more effective killer of 
human breast cancer stem-like cells than paclitaxel (Taxol), a commonly used breast 
cancer chemotherapeutic drug. This study was very interesting and time-consuming, 
because about 16,000 compounds were screened for their ability to kill stem-like breast 
cancer cells (i.e. breast cancer cells passing through an epithelial-mesenchymal transition 
(EMT)) at a greater rate than the control cancer cells. The screen turned up 32 such 
compounds. The researchers winnowed the results down to the most promising and 
focused on one called salinomycin. Stem-like breast cancer cells treated with salinomycin 
were much less able to form new tumors when injected into mice [163]. Further, treatment 
of mice with salinomycin inhibits mammary tumor growth in vivo and induces increased 
epithelial differentiation of tumor cells. In addition, global gene expression analyses show 
that salinomycin treatment results in the loss of expression of breast CSC genes previously 
identified by analyses of breast tissues isolated directly from patients [154]. These findings 
strongly suggest that salinomycin is a selective killer of human cancer stem cells and a new 
promising agent for the elimination of cancer stem cells. 
Discovery of the anticancer properties of salinomycin by Gupta et al. began an 
intensive research on these new properties. Susceptibility of CSCs to salinomycin also 
bolsters the possibility that this drug may target treatment-resistant advanced human 
cancers. A recent study revealed that salinomycin induces massive apoptosis in human 
cancer cells of different origin, but not in normal cells such as human T lymphocytes [155]. 
Moreover, salinomycin is able to induce apoptosis in cancer cells that exhibit resistance to 
apoptosis and anticancer agents by overexpression of Bcl-2, P-glycoprotein or 26S 
proteasomes with enhanced proteolytic activity. Salinomycin activates a distinct and 
unconventional pathway of apoptosis in cancer cells that is not accompanied by cell cycle 
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arrest, and that is independent of tumor suppressor protein p53, caspase activation, the 
CD95/CD95 ligand system and the 26S proteasome [155]. This might be one reason why 
salinomycin can overcome multiple mechanisms of drug and apoptosis resistance in human 
cancer cells. Many cancer cells harbor or acquire multiple mechanisms of apoptosis resis-
tance mediated by the loss of p53 and overexpression of Bcl-2, P-glycoprotein or 26S 
proteasomes with enhanced proteolytic activity [164-166]. Salinomycin, however, appears 
to be capable of overcoming these mechanisms of drug and apoptosis resistance, 
suggesting a possible future use of salinomycin in the treatment of drug-resistant and 
aggressive cancers. 
Recently, the in vitro anticancer activities of salinomycin have been validated 
against the lung cancer cell line A549 [167]. Expression of stem cell markers decreased 
significantly after 24-h treatment with salinomycin. All the results concerning salinomycin 
suggest that it is very promising lung cancer chemotherapeutic. Furthermore, salinomycin 
has also been reported to significantly inhibit stem-like gastric cancer cells with high 
aldehyde dehydrogenase (ALDH) activity. These findings will provide pivotal clue for 
selective chemotherapy on gastric carcinoma [168]. Moreover, one study found that 
salinomycin inhibited osteosarcoma by selectively targeting its stem cells both in vitro and 
in vivo without severe side effects. This finding supports the use of salinomycin for 
elimination of osteosarcoma stem cells and implies a need for further clinical evaluation 
[169]. 
The anticancer effect of salinomycin has been also observed by Dong et al. [170], 
who proved that salinomycin exhibited a significant toxicity toward human colorectal 
cancer (CRC) cell lines, HT29 (IC50 ~ 8 µM ± 0.15) as well as SW480 (IC50 ~ 10 µM ± 
0.03). Furthermore, HT29 cells were more sensitive to salinomycin than oxaliplatin, a 
commonly used CRC chemotherapeutic drug. After treatment with salinomycin, the 
proportion of CD133+ subpopulations in human CRC HT29 and SW480 cells were reduced. 
In addition, salinomycin treatment decreased colony-forming ability and cell motility in 
HT29 cells. Further investigation showed that salinomycin might induce the mesenchymal-
epithelial transition (MET) in HT29 cells. Therefore, this study demonstrates that 
salinomycin not only selectively targets CRC stem cells (i.e. ‘CD133+’ Cell 
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Subpopulations) specifically but also decreases malignant traits (invasion and migration) in 
CRC cell lines. 
All findings from the above-mentioned studies strongly suggest that salinomycin 
has ability to kill cancer stem cells and apoptosis-resistant cancer cells, and would be of 
interest for development of anticancer drug. The number of possible questions, induced by 
a new discovery that a veterinary drug killed 100 times more CSCs than standard 
chemotherapy drugs, will be steadily growing.  
1.4.3 Salinomycin-based combination cancer chemotherapy 
A successful anticancer therapeutic system should eliminate both the differentiated cancer 
cells and the cancer stem cell population. Classical cytotoxic agents may deplete the bulk 
of a cancer but not the inherently chemoresistant CSCs, which ultimately recur and 
metastasize [171]. One ideal anticancer strategy would be to look for agents that target 
both the CSCs and non-CSCs within tumors. Alternatively, it may be preferable to develop 
combination therapies that apply agents with specific toxicity for CSCs together with 
agents that specifically target non-CSC populations within tumors. Therefore, the finding 
of targeting CSCs subpopulation should be improved the current treatments against highly 
aggressive, metastatic, recurrent, and lethal CSCs subpopulation [168]. Currently, 
salinomycin has been shown to inhibit tumor stem cells [154] and overcome drug 
resistance in human cancer cells [155]. These characteristics of salinomycin have the 
potential to be exploited to increasingly sensitize cells to anticancer drugs as part of 
combination chemotherapy. 
The efficacy of combined treatments of salinomycin and gemcitabine in human 
pancreatic cancer cells were recently examined by Zhao´s group, showing that salinomycin 
inhibited the growth of CSCs, while gemcitabine suppressed the viability of non-CSCs 
[172]. Furthermore, combined treatment led to a nearly complete abolishment of both 
CSCs and differentiated cells in vitro. Consistently, in vivo studies showed that 
salinomycin combined with gemcitabine could eliminate the engraftment of human 
pancreatic cancer more effectively than the individual agents. These data indicated that 
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salinomycin could be a promising agent for novel combination therapy for the treatment of 
human pancreatic cancers. 
In 2011, Zhang et al. [173] developed octreotide (Oct)-modified paclitaxel (PTX)-
loaded PEG-b-PCL polymeric micelles (Oct-M-PTX), which can enhance binding to 
somatostatin receptors (SSTR) positive human breast cancer MCF-7 cells, and salinomycin 
(SAL)-loaded PEG-b-PCL polymeric micelles (M-SAL), which can eradicate cancer stem 
cells. After the efficacy of combination therapy using Oct-M-PTX plus M-SAL were 
investigated in vitro and in the MCF-7 xenografts in mice, the results showed that the 
combination treatment was capable of producing a stronger inhibitory effect to the tumors 
by killing the breast cancer cells together with eliminating the breast cancer stem cells 
synchronously. Thus, this combination therapy may provide a potential strategy for the 
treatment of SSTR-overexpressing breast cancers by eradicating breast cancer cells 
together with breast cancer stem cells. 
More recently, one study has demonstrated that targeting HER2 expressing tumors 
with anti-HER2 therapies (trastuzumab) will not necessarily eliminate cancer stem cells 
and may lead to a more aggressive cancer cell phenotype [174]. Combinatorial treatment of 
mammospheres with trastuzumab and salinomycin efficiently targets HER2high cancer cells 
and cancer stem cell population, i.e., HER2low cells. Hence, this study opens a possibility 
for a new combinatorial treatment strategy for heterogeneous breast cancers.  
During the last two years, three successive reports from Yoon´s group have 
demonstrated that salinomycin sensitizes not only doxorubicin (DOX)-, etoposide (ETO)-, 
or radiation-treated cancer cells, but also antimitotic drugs-treated cancer cells [175-177]. 
The mechanisms underlying salinomycin sensitization to DNA-damaging compounds, 
radiation, and microtubule-targeting drugs could be similar and conserved. In addition, 
salinomycin also relatively sensitized verapamil (Ver, a well-known P-glycoprotein 
inhibitor)-resistant cancer cells [176]. These results may contribute to the development of 
Sal-based pharmacological combination therapy for cancer patients. 
1.4.4 Mechanism of anticancer activity of salinomycin  
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The molecular mechanisms of anticancer action induced by salinomycin would be a 
potential interest for a development of anticancer drug. A more complete understanding of 
the salinomycin´s anticancer mechanism could facilitate the therapeutic use of salinomycin 
in cancer patients. It was shown in a high-throughput screen that salinomycin was a highly 
effective agent in the elimination of CSCs and could be used as an anticancer drug, but 
scientists had to admit that the mechanism of action of this compound is unclear [154]. 
Recently, Fuchs et al. reported that salinomycin induces apoptosis and causes growth 
inhibition in diverse types of apoptosis- and chemotherapeutic-resistant cancer cells [155]. 
Salinomycin-mediated apoptosis in these cells is independent of known mediators of the 
cell death signal pathway, such as the p53 tumor suppressor protein, the 26S proteasome 
and the CD95/CD95 ligand system. Further study has showed that salinomycin triggers 
apoptosis by overcoming ATP-binding cassette (ABC) transporter-mediated multidrug 
resistance, as was observed in the case of KG-1a human leukemia stem cell-like cells [178]. 
One of the most important mechanisms of drug resistance in leukemia stem cells and other 
cancer stem cells is the expression of ABC transporters belonging to a highly conserved 
superfamily of transmembrane proteins capable of exporting a wide variety of molecules 
and structurally unrelated chemotherapeutic drugs from the cytosol, thereby conferring 
multidrug resistance, which is a major obstacle to the success of cancer chemotherapy 
[179-181]. As shown in the study, KG-1a cells which are expressed functional ABC 
transporters such as P-glycoprotein (P-gp), BCRP and MRP8, are highly sensitive to 
apoptosis induction by salinomycin. Moreover, salinomycin does not permit long-term 
adaptation of KG-1a cells to apoptosis-inducing concentrations. Thus, salinomycin should 
be regarded as a novel and effective agent for the elimination of leukemia stem cells and 
other tumor cells exhibiting ABC transporter-mediated multidrug resistance.  
Studies performed in 2011 [182] showed that salinomycin induces apoptosis of 
prostate cancer cells by elevating oxidative stress through intracellular reactive oxygen 
species (ROS) production, which is accompanied by decreased mitochondrial membrane 
potential (MMP), translocation of BAX protein to mitochondria, cytochrome c release to 
the cytoplasm, activation of the caspase-3 and cleavage of PARP-1 in androgen-
independent, chemotherapeutic-refractive PC-3 human prostate cancer cells. These results 
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are the first to link elevated oxidative stress and mitochondrial membrane depolarization to 
salinomycin-mediated apoptosis of prostate cancer cells. In addition, another recent report 
[183] also indicates that salinomycin inhibits prostate cancer cell growth and migration by 
reducing the expression of key prostate cancer oncogenes, inducing oxidative stress, 
decreasing the antioxidative capacity and cancer stem cell fraction. Moreover, salinomycin 
exhibits significant growth inhibition and induction of apoptosis in human ovarian cancer 
cells in vitro and in vivo. Salinomycin-induced apoptosis in human ovarian cancer cells 
might be associated with activating p38 MAPK [184]. 
Of note, salinomycin recently has been reported to inhibit Wnt signaling and 
selectively induce apoptosis in chronic lymphocytic leukaemia cells [185]. The Wnt/β-
catenin signaling pathway drives stem cell self-renewal and is involved in the pathogenesis 
of various types of cancer. Aberrant activation of the Wnt signaling pathway in normal 
stem cells can promote their transformation into CSCs [171, 186, 187]. In this study, 
salinomycin potently inhibits proximal Wnt/β-catenin signalling and blocks the 
phosphorylation of the Wnt coreceptor lipoprotein receptor related protein 6 (LRP6) and 
induces its degradation. These results suggest that salinomycin as an inhibitor of Wnt/β-
catenin signaling acts on the Wnt/Fzd/LRP complex and the anticancer effects of 
salinomycin may be at least partially attributable to Wnt inhibition. More recently, it has 
also been found that Wnt/β-catenin signaling pathway may be involved in the targeting of 
salinomycin on osteosarcoma stem cells [169].  
Identifying mechanisms underlying salinomycin sensitization of cancer cells would 
also be an important step in developing Sal-based pharmacological combination cancer 
therapy. Recently performed studies have shown that salinomycin can function as a P-gp 
inhibitor to overcome apoptosis resistance in human cancer cells, including leukaemia stem 
cell-like cells [178, 188]. Efflux pump P-gp can increase the removal of anticancer drugs 
from the cell to reduce cellular damage. Treatment of the multidrug resistance (MDR) cell 
lines with salinomycin restored a normal drug sensitivity of these cells. Another study [176] 
demonstrates that salinomycin could utilize another type of P-gp substrate independent of 
Verapamil (Ver, a well-known P-gp inhibitor), and salinomycin more effectively inhibits 
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P-gp in cancer cells than Ver. In addition, salinomycin sensitized Ver-resistant cancer cells, 
indicating that salinomycin may be useful for treating Ver-resistant cancers.  
The data from three successive reports [175-177] have demonstrated that 
salinomycin can sensitize DOX-, ETO-, radiation-, or antimitotic drugs-treated cancer cells 
through a similar and conserved mechanism, i.e. increasing DNA damage and reducing 
p21 protein levels. Conservation of a sensitization mechanism assumes that salinomycin 
targets the same molecules, even when it is used in different combinations with various 
anticancer treatments. Identifying molecules consistently targeted by salinomycin would be 
beneficial for developing effective anticancer treatments [176]. In addition, salinomycin 
also can sensitize cancer cells to antimitotic drugs by increasing apoptosis, preventing both 
G2 arrest and aneuploidy, and reducing cyclin D1 protein levels [177]. These findings may 
contribute to the development of Sal-based combination therapies for cancer patients. 
Overall, the mechanism of anticancer activity of salinomycin is probably 
complicated but most likely it will soon be explained. The studies about the anticancer 
activity and mechanisms of salinomycin will increase in the near future. 
1.4.5 Toxicity of salinomycin 
Although salinomycin has been widely used as coccidiostat poultry and livestock to 
improve feeding efficiency for more than 30 years [151, 189], its use as a feed additive is 
no longer authorized in the European Union and was never approved in the United States 
[190]. Salinomycin can cause severe neural and muscular toxicity when accidentally fed to 
animals in relatively high doses, as described for chickens [191], turkeys [192], cats [193], 
pigs [194], alpacas [195], and horses [196]. Salinomycin as a positive ionotropic and 
chronotropic agent has been reported to increase cardiac output, left ventricular systolic 
pressure, heart rate, mean arterial pressure, coronary artery vasodilatation and blood flow, 
and plasma catecholamine concentrations as demonstrated in dogs receiving an intravenous 
injection of 150 µg•kg-1 salinomycin [197]. Besides, salinomycin intoxication in human 
beings has been reported recently [190, 198]. Accidental ingestion of an estimated 1 mg/kg 
of salinomycin resulted in a 6-week hospital admission with prolonged rhabdomyolysis, 
pain, and disability [198]. Other clinical manifestations included dizziness, nausea, 
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vomiting, stomachache, diarrhea, limb anesthesia, weakness, and dark red to brown urine 
[190]. 
Salinomycin has never been used as a drug in humans, probably due to the 
considerable toxicity observed in mammals [193, 194, 198, 199]. Additionally, up to now, 
the precise mechanism of salinomycin-mediated toxicity is unknown. Effects of 
salinomycin on the human organisms have also not been examined [157]. In 2011, one 
study [200] proved that salinomycin in concentrations effective against CSCs exerts 
profound toxicity towards nervous cells (dorsal root ganglia as well as Schwann cells). 
This toxic effect is mediated by elevated cytosolic Na+ concentrations, which in turn cause 
an increase in cytosolic Ca2+ by means of Na+/Ca2+ exchangers (NCXs) in the plasma 
membrane as well as the mitochondria. Therefore, salinomycin strongly reduces cell 
viability by means of calpain and cytochrome c-mediated caspase 9 and subsequent 
caspase 3 activation [200]. These findings expand the knowledge of the mechanisms 
involved in the pathogenesis of salinomycin-induced peripheral neuropathy and provide a 
mechanism for neuroprotection through inhibition of mitochondrial NCXs. Thus new 
strategies for a clinical translation of salinomycin therapy may be developed [200]. In view 
of the severe toxicity of salinomycin, future studies with salinomycin in humans should be 
designed carefully. 
In summary, recently the potassium ionophore antibiotic salinomycin has been 
shown to kill human cancer stem cells, sensitize cancer cells to anticancer drugs, and 
induce apoptosis in drug-resistant cancer cells. One important caveat for the potential 
clinical use of salinomycin is its severe toxicity. All the aforementioned studies will 
prompt scientists to search for a new group of salinomycin derivatives which will be more 
effective in coordination of biologically important metal cations and less toxic especially 
for humans. A new chapter in chemistry and biology of ionophores has been opened, and 
the investigation of the structure, safety, toxicity, pharmacology and anticancer activity of 
this group of compounds in humans is a challenge for the coming years. 
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2. AIM OF THE STUDY 
Ovarian cancer remains a leading cause of death from gynecological malignancy [201]. 
The incidence of ovarian cancer increases with age and 70% of patients present with 
advanced disease. Current standard of care including surgery and chemotherapy has had 
very limited success in treatment of the patients diagnosed with late stage disease [202, 
203]. Long-term administration of cisplatin has been shown to result in the development of 
chemotherapeutic drug resistance in the cancer cell population [204, 205]. Therefore, 
searching for alternative agents to overcome chemoresistance during the treatment of 
ovarian cancer is essential. Salinomycin, a polyether ionophore antibiotic that has recently 
been shown not only to kill human breast cancer stem cell-like cells [154], but also to 
induce apoptosis and overcome multiple mechanisms of resistance to apoptosis in human 
cancer cells [155]. These results strongly suggested that salinomycin should be regarded as 
an anticancer compound. 
The major aims of this study were: 
• To evaluate in vitro anti-tumoral properties of salinomycin in human ovarian cancer 
cell lines (especially in cisplatin-resistant human ovarian cancer cell line C13 and its 
parent cisplatin-sensitive OV2008 cells) and to investigate the effects of salinomycin 
on tumor cell growth, apoptosis and cell cycle parameters. 
 
• To establish human ovarian cancer cell lines (OV2008 or C13) xenograft tumor animal 
model, to observe the therapeutic effect of salinomycin in human ovarian cancer cell 
line xenotransplanted cancer in vivo, and to detect apoptosis in tumor tissue in situ. 
 
• To investigate the effect of salinomycin on phosphoproteins levels in ovarian cancer 
cell lines (OV2008 and C13), to better understand the signal pathways involved in 
salinomycin-induced growth-inhibitory effect and apoptosis in ovarian cancer cell lines, 
and to derive mechanistic insights into the action of salinomycin. 
AIM OF THE STUDY 
 
 
36 
Materials and methods used in this study were described in detail in each 
manuscript. The experimental work were mainly based on: 1) in vitro human ovarian 
cancer cell lines culture, including cisplatin-resistant human ovarian cancer cell lines; 2) in 
vivo human ovarian cancer cell lines (OV2008 or C13) murine xenograft model. 
PUBLISHED RESEARCH MANUSCRIPTS 
 
37 
3. PUBLISHED MANUSCRIPTS AND SUPPLEMENTARY DATA 
3.1 Published research manuscript 
Title:  Effects of salinomycin on human ovarian cancer cell line OV2008 are 
associated with modulating p38 MAPK 
Authors:  Bei Zhang, Xueya Wang, Fengfeng Cai, Weijie Chen, Uli Loesch, Johannes 
Bitzer and Xiao Yan Zhong 
Journal: Tumour Biol. 2012 Dec; 33(6):1855-62.  
Summary: Ovarian cancer remains a leading cause of death from gynecological 
malignancy. The therapeutic effect of ovarian cancer is undesirable. 
Salinomycin is a polyether ionophore antibiotic that has recently been 
reported as a selective inhibitor of cancer stem cell and is considered to be a 
potential anticancer compound for cancer chemoprevention and cancer 
therapy. In this study, we investigated the anticancer effect and mechanism 
of salinomycin on human ovarian cancer cell line OV2008 in vitro and in 
vivo. The results of this research demonstrated that salinomycin is a potent 
compound against human ovarian cancer cell line OV2008 in vitro and 
indicates significant in vivo efficacy in tumor (OV2008) xenograft model. 
Salinomycin can inhibit the growth of ovarian cancer cell line OV2008 
efficiently through induction of apoptosis, which is not accompanied by cell 
cycle arrest, but possibly is associated with activating p38 MAPK and 
merits further investigations.  
Author contributions:  
Bei Zhang was involved in experimental design, performing the 
experiments, data analysis and writing the manuscript. 
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Abstract 
Objective. To investigate the anticancer effect and mechanism of salinomycin, a selective 
inhibitor of cancer stem cell, on human ovarian cancer cell line OV2008 in vitro and in 
vivo. 
Methods. The growth inhibitory effect of salinomycin on ovarian cancer cell line OV2008 
was determined by measuring cell viability using the resazurin reduction assay. Apoptotic 
nuclear morphology was visualized by DAPI staining technique. The percentages of 
apoptotic cells and cell cycle parameters were detected by flow cytometry. The activation 
of p38 MAPK was analyzed by Bio-Plex phosphoprotein assay. In vivo activity of 
salinomycin was assayed through tumor growth. 
Results. Salinomycin caused concentration- (0.01µM-200µM) and time-dependent (24-
72hr) growth inhibitory effects in OV2008. Cell nuclear morphology observations showed 
that salinomycin-treated OV2008 cells displayed the typical apoptotic characteristics. 
Salinomycin significantly increased the percentages of apoptotic cells in OV2008, showing 
a concentration- and time-dependent manner. There was no cell cycle arrest in the G1/G0, 
S and G2/M phases between salinomycin-treated cells and control cells. Salinomycin also 
enhanced the phosphorylation of p38 MAPK. Moreover, salinomycin significantly 
inhibited the growth of the ovarian xenograft tumors. 
Conclusion. Salinomycin exhibited significant growth-inhibition and induction of 
apoptosis in human ovarian cancer cell line OV2008. The data suggested that salinomycin-
induced apoptosis in OV2008 might be associated with activating p38 MAPK and merits 
further investigations.  
 
Keywords: Salinomycin; Ovarian cancer; Growth inhibition; Apoptosis; p38 MAPK; 
Tumor xenografts 
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Introduction 
Salinomycin is a 751 Da monocarboxylic polyether antibiotic belonging to the group of 
ionophores that isolated from Streptomyces albus (strain No. 80614) [1]. Salinomycin acts 
in different biological membranes, including mitochondrial and cytoplasmic membranes, 
as an ionophore with a stringent selectivity for monovalent cations and a considerable 
preference for potassium ions [2,3]. Salinomycin exhibits a large-spectrum antimicrobial 
activity including anticoccidial property [4,5]. It is commonly used as a coccidiostat in 
poultry and other livestock and is fed to ruminants to improve nutrient absorption and feed 
efficiency [6]. Recently, salinomycin has been reported to selectively deplete human breast 
cancer stem cells from tumorspheres and to inhibit the mammary tumor growth and 
metastasis in vivo [7]. Another recent report showed that salinomycin induces apoptosis in 
human cancer cells, including those that display wild-type p53 or p53 mutation and multi-
drug resistance due to overexpression of Bcl-2, P-glycoprotein or 26S proteasomes with 
deregulated proteolytic activity [8]. These results strongly suggested that salinomycin 
should be regarded as an anticancer compound. The mechanism of anticancer action of 
salinomycin is not completely understood. One study showed salinomycin activates a 
particular apoptotic pathway not accompanied by cell cycle arrest and independent of 
tumor suppressor protein p53, caspase activation, the CD95/CD95L system and the 
proteasome [8]. More recently, salinomycin was reported to overcome ABC transporter-
mediated multidrug and apoptosis resistance [9] and act as a potent inhibitor of multidrug 
resistance gp170 [10]. Furthermore, a recent study uncovered that salinomycin inhibits the 
activity of the Wnt signaling pathway, recently appointed as an essential regulator of CSC 
(cancer stem cell) properties in chronic lymphocytic leukemia cells [11].  
Ovarian cancer remains a leading cause of death from gynecological malignancy, 
with more than 204,000 new cases and 125,000 deaths each year, accounting for 4% of all 
cancer cases and 4.2% of all cancer deaths in women around the world [12]. The high 
mortality rate of women with ovarian cancer has been attributed both to lack of early 
detection and to development of chemoresistance during treatment [13,14]. Current 
standard of care including surgery and chemotherapy has had very limited success in 
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treatment of the patients diagnosed with late stage disease [15,16]. The aims of this study 
were (1) to determine the anticancer biological activity of salinomycin toward human 
ovarian cancer cell line OV2008; (2) to derive mechanistic insights into the action of 
salinomycin; and (3) to determine whether salinomycin would significantly inhibit tumor 
growth in an in vivo model of ovarian cancer. The studies were conducted using human 
ovarian cancer cell line OV2008 and its murine xenograft model. The results showed 
salinomycin inhibited cell-growth and induced apoptosis in ovarian cancer cell line 
OV2008 in vitro and suppressed tumor growth in vivo as well. The salinomycin-induced 
apoptosis in ovarian cancer cell line OV2008 could be mediated through an increase in the 
activation of p38 MAPK. 
Materials and Methods 
Cell line and culture 
The OV2008 human epithelial ovarian cancer cell line was kindly supplied by Dr. Gaetano 
Marverti (University of Modena and Reggio Emilia, Italy) and routinely grown in 
humidified condition at 5% CO2 and 37°C, incubated with RPMI 1640 standard medium 
supplemented with 10% fetal bovine serum (FBS), antibiotics (100IU/ml penicillin and 
100µg/ml streptomycin) and L-glutamine (2mM). Exponentially growing cells were used 
throughout the study. All these reagents were from Invitrogen (Carlsbad, CA).  
Growth inhibition assay  
The growth inhibitory effect of salinomycin on OV2008 was determined by measuring cell 
viability using the resazurin reduction assay. Briefly, Cells were seeded in 100µl media in 
96-well microtitre plates at a density of 5000/well. Following overnight incubation, cells 
were exposed to a range of different concentrations of salinomycin (Sigma-Aldrich, S4526 
and 0.1% DMSO as solvent control) and grown at 37°C under a 5% CO2 atmosphere for 
24-72hr. 5µl of 0.02% (w/v) Resazurin (Sigma-Aldrich, R7017) in phosphate buffered 
saline (PBS) was then added to each well and incubation was continued for an additional 
2hr. Finally, fluorescence was read using a spectramax GEMINI XS microplate reader 
(λexc=544nm, λem=590nm).    
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Cell nuclear morphology observations 
Exponentially growing cells were incubated with salinomycin for 12hr, 24hr and 36hr, 
respectively, and equal volumes of solvent (0.1% DMSO) as control. Apoptotic nuclear 
morphology was visualized by DAPI staining technique. Cells (1×105) were collected on 
the slide using cytospin, then fixed with 3.7% of paraformaldehyde (#28906, Pierce) for 
15min at room temperature, washed three times with PBS and immersed in 0.1% of Triton 
X-100 (Sigma-Aldrich, T8787) for 15min. Thus, paraformaldehyde-fixed cells were 
stained using 1:1000 DAPI (4, 6–diamino-2-phenylindole; 1 mg/ml in ddH2O; Invitrogen, 
D29410) in ddH2O for 5 minutes under dark at room temperature. After three times of 
washing with PBS, cells were coverslipped with a florescence mounting medium (Dako, 
S3023) and visualized using fluorescence microscope (Olympus B×51, Japan). 
Cell apoptosis detection  
Cell apoptosis was studied by using the annexin V-fluorescein isothiocyanate 
(FITC)/propidium iodide (PI) apoptosis assay kit (BD pharmingen) in combination with 
flow cytometry (CyAn ADP, Dako). After cells were incubated with salinomycin for 12hr, 
24hr and 36hr, respectively, and with solvent control (0.1% DMSO) as well, they were 
harvested by quick trypsinization to minimize potentially high annexin V background 
levels in adherent cells. Cells were then washed twice with cold PBS and re-suspended in 
binding buffer at a concentration of 1×106 cells/ml. 100µl cells were taken to stain with 5µl 
annexin V/FITC and 5µl PI and incubated in dark at room temperature for 15min. Then 
400µl binding buffer was added before cells were analyzed by flow cytometry. Cells 
negative for both annexin V and PI are viable, annexin V+/PI- cells are in early apoptosis, 
and annexinV+/PI+ cells are necrotic or in late apoptosis. The percentages of apoptotic cells 
were analyzed by Flowjo software. 
Cell cycle distribution analysis  
To evaluate cell cycle profile, cells (about 1×106 cells), pretreated with salinomycin for 
12hr and 24hr (0.1% DMSO as a solvent control), were harvested, washed twice with PBS, 
then fixed and stored in ice-cold 70% (v/v) ethanol at -20°C. Prior to analysis, samples 
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were washed again with PBS and then incubated in propidium iodide/Rnase staining buffer 
(BD pharmingen) at room temperature in the dark for at least 15 min. After filtration to 
remove cellular debris, the single-cell suspensions were analyzed on a flow cytometer. Cell 
cycle parameters were analyzed using Flowjo software.  
Phosphoprotein assay 
Phosphoprotein was measured in duplicate using a bead-based multiplex assay (Bio-Plex 
Phosphoprotein Detection, Bio-Rad, Hercules, USA), according to the manufacturer’s 
instructions [17,18]. After OV2008 cells were cultured with salinomycin or with solvent 
control (0.1% DMSO) for the indicated time interval, cells were rinsed with ice-cold cell 
wash buffer and then lysed in lysing solution. The lysate was collected and centrifuged at 
4500g for 20 min at 4°C. The protein concentration was measured and calculated with a 
DC (detergent compatible) protein assay (Bio-Rad). The Bio-Plex assay was applied to 
detect and quantify phosphoproteins of p38 mitogen-activated protein kinase (p38 MAPK). 
The prepared first antibody with coupled beads was captured under 96-well plates, and 
then samples (15 µg proteins each) were incubated with the coupled beads overnight at 
room temperature. On the next day, after washing, the samples were incubated with biotin-
labelled detection antibodies followed by further incubation with the PE-labelled 
streptavidin reporter. The level of phosphoproteins bound to the beads was indicated by the 
intensity of the reporter signal. The signal was acquired and analyzed using Bio-Plex 
Manager software (Bio-Rad) interfaced with a Bio-Plex 200 system (Bio-Rad). In this 
assay, the lysates of Phosphotase-Treated HeLa cells and UV-Treated HEK293 cells, 
provided by the Bio-Plex phosphoprotein assay, were used as the background control and 
Phospho-p38 MAPK (Thr180/Tyr182) positive control, respectively. This experiment was 
repeated in duplicate. 
Ovarian cancer tumor xenografts in mice 
Female mice of NOD/SCID were in-house breeding from the Animal Center 
(Tierversuchsstation) at the Department of Biomedicine, University Hospital of Basel and 
used at 6 weeks of age. All mouse procedures were approved by Cantonal Veterinary 
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Office (Kantonales Veterinäramt) and performed in accordance with the regulations 
concerning animal experiments. For in vivo salinomycin treatment study, cultured OV2008 
cells (2×106 cells per mouse in 0.1ml saline) were subcutaneously injected into the back of 
NOD/SCID mice. On the day after tumor cells injection, mice were divided into two 
groups of 5 mice each. Treatment was initiated 24hr after injection. The two experimental 
groups were administrated with salinomycin (5mg/kg) [7] and 5% ethanol (vehicle), 
respectively, by intraperitoneal injection on every other day for 3 weeks. The size of the 
tumor was measured every 2 days using a digital vernier caliper. Tumor volume was 
estimated by the following formula: volume= (a × b2) × π/6, where a and b are major and 
minor axes of the tumor. 
Statistical analysis 
All data were expressed as mean values ± standard deviation. Growth-inhibitory curve 
were analyzed using GraphPad Prism 5.01 Software. Comparisons among groups were 
performed by Student’s t-test. The significance level was set at P<0.05. 
Results 
Growth-inhibitory effect of salinomycin on ovarian cancer cell line OV2008  
The growth-inhibitory effect of salinomycin against OV2008 cell line is shown in Fig.1. 
The effect of incubation time and concentration on viability of OV2008 cells by 
salinomycin was studied. Cells were exposed for 24, 48 or 72hr to salinomycin at 
(0.01µM-200µM) concentration range, and cell viability measured by the resazurin 
reduction assay. In this study, salinomycin inhibited the growth of OV2008 cells in a 
concentration- and time-dependent pattern. IC50 (95% confidence interval) of salinomycin 
on OV2008 cell line for 24hr, 48hr and 72hr was 7.44 (6.80 to 8.14), 4.78 (4.12 to 5.55) 
and 3.20 (2.90 to 3.53), respectively. 
Effect of salinomycin on cell morphology and nuclear change 
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Treating OV2008 cells with 20µM or 50µM salinomycin for 12hr, 24hr and 36hr, 
respectively, resulted in the detachment of cells from the tissue culture plates as well as 
cell death. In order to examine whether cells died due to apoptosis mechanisms, the nuclear 
morphological changes were observed under fluorescence microscope. The nuclei in 
control cells exhibited equal distribution of the chromatin, while salinomycin-treated cells 
showed the characteristic morphologic changes of apoptosis, such as condensed chromatin, 
nuclear fragmentation and blebbing (Fig.S1). Therefore, these morphological changes 
suggested the occurrence of apoptosis in OV2008 cells after treated with salinomycin. 
Effect of salinomycin on tumor cell apoptosis and cell cycle 
Salinomycin-treated OV2008 cells were analyzed by flow cytometry which can distinguish 
between early apoptosis or late apoptosis of cells after cells were stained simultaneously 
with annexin V and PI. Compared to control, salinomycin treatment significantly increased 
the percentages of apoptotic cells in OV2008, showing a concentration- and time-
dependent manner (Fig.2A). In control culture, 3.36±0.04% cells were in early apoptosis 
stage whereas 10.09±0.16% cells were in late apoptosis stage. After cells were treated with 
50µM salinomycin for 12hr, the percentages of apoptotic cells at early phase increased to 
6.95±1.82% and that of late phase increased to 13.03±0.38%. Whereas, when cells treated 
with salinomycin for 24 and 36hr, 9.70±1.77% and 9.35±1.79% cells were in early 
apoptosis, and 24.5±1.71% and 30.53±1.55% cells were in late apoptosis. A time-
dependent increase in the number of apoptotic cells was observed (Fig.2B). These results 
clearly indicate that salinomycin evoked apoptosis in OV2008 cells. 
Effect of different concentrations of salinomycin (20 and 50µM) on the cell cycle 
phases was investigated in OV2008 cells cultured over different times (12 and 24hr) by 
DNA content analysis, by flow cytometry. The results showed that the percentages of the 
cell population in the sub-G1 phase were significantly higher in salinomycin-treated 
OV2008 cells with a concentration-dependent fashion, whereas the percentages of cells in 
other phases (G1/G0, S and G2/M phases) were almost reduced, in comparison with 
control (Fig.3). These effects were similar at 12 and 24hr (Fig.3). The dramatic 
accumulation of cells in sub-G1 phase was another marker for apoptosis, which further 
PUBLISHED RESEARCH MANUSCRIPTS 
 
 
46 
confirmed the results of annexin V/PI assay.  Additionally, there was no cell cycle arrest in 
G1/G0, S and G2/M phases between salinomycin-treated cells and control cells, suggesting 
that salinomycin inhibits the cellular proliferation of OV2008 cells not accompanied by 
cell cycle arrest. 
Effect of salinomycin on phosphorylation of p38 MAPK in OV2008 cells 
To investigate the effect of salinomycin on p38 MAPK activity in ovarian cancer cell line 
OV2008, the regulation of p38 MAPK phosphorylation by salinomycin was examined 
using Bio-Plex phosphoprotein assay. The results showed phosphorylation of p38 MAPK 
in OV2008 cells was enhanced by salinomycin (20µM) after 12, 24 and 36hr of incubation 
(Fig.4A), while a marked concentration-dependent increase in the p38 MAPK 
phosphorylation was observed following salinomycin exposure for 24hr (Fig.4B). These 
findings suggest that salinomycin-induced growth-inhibitory effect and apoptosis in 
OV2008 could be mediated through the alteration of phosphorylation of p38 MAPK. 
Evaluation of antitumor activity of salinomycin in vivo   
Based on the in vitro results, which showed significant cytotoxicity of salinomycin to 
human ovarian cancer cell line OV2008, the in vivo antitumor efficacy of salinomycin was 
further evaluated in a human ovarian tumor xenograft grown in the back of mice. The mice 
were treated with salinomycin and the change in tumor volume after first injection was 
followed for 21 days (Fig.5A). Compared with vehicle-treated controls, a significant 
reduction in the tumor volume was observed in the mice treated with salinomycin (Fig.5C). 
When the test came to the end, in OV2008 tumor model, the tumor volume of salinomycin 
therapy groups and controls was 122.3±41.4 mm3 and 252.2±55.29 mm3, respectively 
(P<0.01; Fig.5B).   
Discussion 
The present study demonstrated that salinomycin inhibited the growth of human ovarian 
cancer cell line OV2008 in vitro and in vivo. The growth inhibition effects of salinomycin 
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and salinomycin-induced apoptosis in human ovarian cancer cell line OV2008 could 
correlate with modulating p38 MAPK.  
Apoptosis, or programmed cell death, is an important homeostatic mechanism that 
balances cell division, cell death and maintains the appropriate cell number in the body 
[19]. Therefore, searching for agents which trigger apoptosis of tumor cells has become an 
attractive strategy in anticancer drug discovery [20]. Apoptosis is characterized 
morphologically by cell shrinkage and loss of contact with neighboring cells, formation of 
cytoplasmic vacuoles, plasma and nuclear membrane blebbing, chromatin condensation, 
and formation of apoptotic bodies [21]. In the present investigation, after OV2008 cells 
were treated with salinomycin, the fluorescence microscopic observations clearly indicated 
these apoptotic characteristics (Fig.S1). Furthermore, flow cytometry results, from both 
annexin V/PI assay (Fig.2) and sub-G1 populations in cell cycle analysis (Fig.3), further 
evidenced a concentration- and time-dependent increase in the percentage of apoptotic 
subpopulations after salinomycin treatment. These results provided evidence that 
salinomycin triggered apoptosis in OV2008 cells, which resembles previous report on 
various human cancer cells such as leukemia cells [8,9].   
Cell cycle control plays a critical role in the regulation of tumor cell proliferation. 
Many anticancer agents and DNA-damaging agents arrest the cell cycle at the G0/G1, S, or 
G2/M phase and then induce apoptotic cell death [22,23]. From the results of present 
study, it appeared that no cell cycle arrest in G1/G0, S and G2/M phases was observed 
between salinomycin-treated OV2008 cells and control cells (Fig.3), which confirms 
previous finding that salinomycin activates a particular apoptotic pathway not 
accompanied by cell cycle arrest [8]. 
To better understand the signal pathways involved in salinomycin-induced growth-
inhibitory effect and apoptosis in OV2008, we investigated the possible involvement of 
p38 MAPK activity. To address this issue, phosphorylation of p38 MAPK was determined 
by Bio-Plex assays with Luminex technology, which contain dyed beads conjugated with 
monoclonal antibodies specific for a target protein or peptide such as a cytokine or a 
phosphoprotein. The antibodies used in these assays undergo rigorous optimization to 
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ensure the highest degree of sensitivity, specificity, and reproducibility. Recently, using 
optimized standard operating procedures regarding sample size and total protein 
concentration range and monoclonal antibodies used for immunoanalysis, and on the basis 
of the US Food and Drug Administration guidelines, Bio-Plex phosphoprotein array intra-
assay and inter-assay coefficients of variation revealed good reproducibility of the 
technique and the results achieved using Bio-Plex phosphoprotein array analyses 
significantly correlated (P<0.001) with those obtained with numerized western blot 
analyses [18]. Furthermore, Bland-Altman analyses clearly demonstrated that Bio-Plex 
phosphoprotein array could be used instead of western blot providing a unique way of 
analyzing multiple phosphoprotein expression in small specimens. 
The p38 MAPK pathway is implicated in cancer cell apoptosis and is induced by 
several chemotherapeutic drugs [24,25]. We found there are marked time-dependent and 
concentration-dependent increases in the phosphorylation of p38 MAPK following 
salinomycin treatment in OV2008 cells (Fig.4). This result suggests that the activation of 
p38 MAPK appears to contribute to the proapoptotic effect of salinomycin in OV2008 
cells and that the activation of the p38 MAPK pathway might play a causal role in the 
salinomycin-induced apoptosis in ovarian cancer cell line OV2008. However, detailed 
downstream and upstream signaling molecules of p38 MAPK modulated by salinomycin 
are not known and warranted further investigations. 
In the present study, the xenografts of human OV2008 ovarian cancer model 
showed very good efficacy when treated with salinomycin (Fig.5). Although, we have not 
yet attempted to ascertain the mechanism of cell death in the xenograft tumor model, it 
remains possible that cell apoptosis induced by salinomycin may account for some of the 
observed reduction in tumor growth rate and needs further investigations. Additionally, 
considering one ovarian cell line was involved in the present study, we also believe that 
further in vitro and in vivo studies with salinomycin in different characterized ovarian 
cancer cell lines, such as p53 mutation cell lines, drug-resistant (MDR overexpression) cell 
lines are warranted to enhance our understanding of this promising antitumorigenic 
compound. 
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Overall, the results of this research demonstrated that salinomycin is a potent 
compound against human ovarian cancer cell line OV2008 in vitro and indicates 
significant in vivo efficacy in tumor (OV2008) xenograft model. Salinomycin can inhibit 
the growth of ovarian cancer cell line OV2008 efficiently through induction of apoptosis, 
which is not accompanied by cell cycle arrest, but possibly is associated with activating 
p38 MAPK and merits further investigations.  
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Fig.1 Effect of salinomycin on cell viability in human ovarian cancer cell line OV2008   Cells were 
exposed to salinomycin at concentrations (0.01-200µM, 0.1% DMSO as solvent control) for 24, 48 and 
72hours and cell viability measured by resazurin reduction assay. Results are Mean±SD of quadruplicates 
from one of three independent experiments 
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Fig.2 Effect of salinomycin on cell apoptosis in OV2008 cells   After cells were treated with 20µM or 50µM 
salinomycin for 12hr, 24hr and 36hr, respectively, and with solvent control (0.1% DMSO) as well, the 
percentage of apoptotic subpopulations (A) was determined by flow cytometry analysis based on mean 
values obtained from three independent experiments. Results are expressed as Mean±SD. ‘*’ and ‘**’: 
Significant difference from control of time point (P<0.05 and P<0.01, respectively). ‘∆’ and ‘∆∆’: Significant 
difference from 0hr control (P<0.05 and P<0.01, respectively). (B) represent flow cytometry results showing 
a time-dependent increase in the number of apoptotic cells after cells were treated with 50µM salinomycin 
for 12hr (b), 24hr (c),  36hr (d) and 0hr as control (a) 
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Fig.3 Effect of salinomycin on cell cycle distribution in OV2008 cells   Cells were treated with 20µM or 
50µM salinomycin for 12hr (A) and 24hr (B), and with 0.1% DMSO as a solvent control. The percentages of 
each cell cycle were evaluated by flow cytometry based on mean values obtained from three independent 
experiments. Results are expressed as Mean±SD. ‘*’ and ‘**’: Significant difference from control (P<0.05 
and P<0.01, respectively) 
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Fig.4 Effect of salinomycin on phospho-p38 MAPK level in OV2008 cells   (A). The phospho-p38 MAPK 
level in OV2008 cells was assessed by the Bio-Plex assay at the indicated intervals after 20µM salinomycin 
treatment (0.1% DMSO as solvent control). After two washes with ice-cold cell wash buffer, monolayer cells 
were lysed. The fluorescence intensity of phospho-p38 MAPK in OV2008 was counted by Bio-Plex 
Suspension Array System. (B). The OV2008 cells were incubated with salinomycin (1, 5, 10, 20, 50µM) or 
with solvent control (0.1% DMSO) for 24hours and phosphoprotein analysis was performed as described 
above. The ‘….’ line shows the signal intensity of Phosphotase-Treated HeLa cells as a background control. 
The ‘----’ line shows the signal intensity of positive control. Results are expressed as Mean±SD 
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Fig.5 Antitumor activity of salinomycin on NOD/SCID mice bearing human OV2008 cells    (A). Tumor-
growth curves of the mice treating with salinomycin (5mg/kg) and vehicle control (5% Ethanol). (B). Final 
volume of tumors in salinomycin- and vehicle-treated animals on the 21th day after tumor injection. Data are 
presented as Mean±SD of tumor volumes (n=5). ‘**’: Significant difference from vehicle control (P<0.01). 
(C). One of the vehicle control group mice (up) and one of the salinomycin-treated group mice (down). 
Tumor size in salinomycin-treated mouse (down) was significantly reduced relative to tumor in vehicle-
treated mouse (up). Black bar indicates 1cm 
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Fig.S1 Cell nucleus morphology observation after salinomycin treatment in OV2008 as indicated by DAPI 
staining   0hr control cells (a) and cells treated with 50µM salinomycin for 12hr (b), 24hr (c) and 36hr (d) 
were collected by cytospin, fixed, permeabilized and stained with DAPI to visualize the nucleus (blue) under 
fluorescent microscope (400×). Apoptotic features (condensed chromatin, nuclear fragmentation and 
blebbing) were found (arrow). White bars indicate 10µm 
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Abstract.  
The therapeutic effect of ovarian cancer is undesirable. In order to search for alternative 
agents to overcome chemoresistance during the treatment of ovarian cancer, this study 
aims at exploring the anticancer effects and mechanism of salinomycin, a selective 
inhibitor of cancer stem cell, on cisplatin-resistant human ovarian cancer cell line in vitro 
and in vivo. Concentration- (0.01 µM-200 µM) and time-dependent (24-72 h) growth 
inhibitory effects of salinomycin were observed in 6 ovarian cancer cell lines (OV2008, 
C13, A2780, A2780-cp, SKOV3 and OVCAR3) by measuring cell viability using the 
resazurin reduction assay. IC50 (24 h) range of salinomycin on these 6 cell lines was 1.7-
7.4 µM. After cisplatin-resistant C13 cells were treated with salinomycin, the percentages 
of apoptotic cells determined by flow cytometry were significantly increased, showing a 
concentration- and time-dependent manner. But no cell cycle arrest in the G1/G0, S and 
G2/M phases was detected between salinomycin-treated cells and control cells. Bio-Plex 
phosphoprotein 5-plex assay (Akt, IκB-α, ERK1/2, JNK and p38 MAPK) revealed a 
marked time-dependent and concentration-dependent increase in the phosphorylation of 
p38 MAPK following salinomycin treatment. Moreover, salinomycin significantly 
suppressed the growth of tumors in tumor xenograft model. These findings suggest that 
salinomycin can inhibit the growth of cisplatin-resistant human ovarian cancer cell line 
efficiently through induction of apoptosis, which might be associated with activation of 
p38 MAPK. 
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Introduction 
Ovarian cancer remains a leading cause of death from gynecological malignancy, with 
more than 204,000 new cases and 125,000 deaths each year, accounting for 4% of all 
cancer cases and 4.2% of all cancer deaths in women around the world (1). The incidence 
of ovarian cancer increases with age and more than 70% of the patients are diagnosed with 
late stage disease after distant metastasis has occurred. The 5-year survival rate for the 
patients diagnosed with late stage disease is less than 20% even with extensive surgery and 
chemotherapy (2, 3). Chemotherapy with administration of cisplatin (cis-
diamminedichloroplatinum (II)) or cisplatin in combination with taxanes is the current 
standard of care (4, 5). Despite the fact that most of the ovarian tumors are sensitive to 
chemotherapy for the first time (6, 7), long-term administration of cisplatin has been 
shown to result in the development of chemotherapeutic drug resistance in the cancer cell 
population (8, 9). Cisplatin resistance is a major hurdle to successful therapy of recurrent 
ovarian tumors and responsible for poor long-term overall survival (6, 7). The suggested 
mechanisms for cisplatin resistance include the increase in intracellular thiols in the redox 
pathway (10), defects in the apoptotic pathway and the altered activation of signaling 
pathways, such as PI3K/Akt (11), MAPK (12), or NF-κB (13). Several groups have 
targeted these pathways in an attempt to circumvent the cisplatin resistance (13, 14). 
Salinomycin is a 751 Da monocarboxylic polyether antibiotic belonging to the 
group of ionophores that isolated from Streptomyces albus (strain No. 80614) (15). It is 
commonly used as a coccidiostat in poultry and other livestock and is fed to ruminants to 
improve nutrient absorption and feed efficiency (16). Recently, salinomycin has been 
reported to selectively deplete human breast cancer stem cells from tumorspheres and to 
inhibit the mammary tumor growth and metastasis in vivo (17). Another recent report 
showed that salinomycin induces apoptosis in human cancer cells, including those that 
display wild-type p53 or p53 mutation and multi-drug resistance due to overexpression of 
Bcl-2, P-glycoprotein or 26S proteasomes with deregulated proteolytic activity (18). These 
results strongly suggested that salinomycin should be regarded as an anticancer compound. 
The mechanism of anticancer action of salinomycin is not completely understood. One 
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study showed salinomycin activates a particular apoptotic pathway not accompanied by 
cell cycle arrest and independent of tumor suppressor protein p53, caspase activation, the 
CD95/CD95L system and the proteasome (18). More recently, salinomycin was reported to 
overcome ABC transporter-mediated multidrug and apoptosis resistance (19) and act as a 
potent inhibitor of multidrug resistance gp170 (20). Furthermore, a recent study uncovered 
that salinomycin inhibits the activity of the Wnt signaling pathway, recently appointed as 
an essential regulator of CSC (cancer stem cell) properties in chronic lymphocytic 
leukemia cells (21).  
The purposes of this study were to determine the anticancer biological activity of 
salinomycin toward cisplatin-resistant human ovarian cancer cell line and its tumor 
xenograft model, and to derive mechanistic insights into the action of salinomycin as well. 
The results showed salinomycin inhibited cell-growth and induced apoptosis in cisplatin-
resistant human ovarian cancer cell line in vitro and suppressed tumor growth in vivo as 
well. The salinomycin-induced apoptosis in cisplatin-resistant ovarian cancer cell line 
could correlate with an increase in the activation of p38 MAPK.  
Materials and Methods 
Cell lines and culture 
The six ovarian cancer cell lines used in this study were OV2008, C13, A2780, A2780-cp 
(A/CP), SKOV3 (p53-negative) and OVCAR3 (p53-mutant). Two pairs of cisplatin-
sensitive and cisplatin-resistant ovarian cancer cell lines (OV2008 and C13, A2780 and 
A/CP, respectively) were kindly supplied by Dr. Gaetano Marverti (University of Modena 
and Reggio Emilia, Italy). All the cell lines were routinely grown in humidified condition 
at 5% CO2 and 37°C, incubated with RPMI 1640 standard medium supplemented with 
10% fetal bovine serum (FBS), antibiotics (100 IU/ml penicillin and 100 µg/ml 
streptomycin) and L-glutamine (2 mM). Exponentially growing cells were used throughout 
the study. All these reagents were supplied by Invitrogen (Carlsbad, CA).  
Growth inhibition assay  
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The growth inhibitory effects of salinomycin or cisplatin on 6 ovarian cancer cell lines 
were determined by measuring cell viability using the resazurin reduction assay. Briefly, 
cells were seeded in 100 µl media in 96-well microtitre plates at a density of 5000 
cells/well. Following overnight incubation, cells were exposed to a range of different 
concentrations of salinomycin (Sigma-Aldrich, S4526) or cisplatin (``Ebewe`` 0.5 mg/ml, 
Ebewe Pharma Schweiz AG) and grown at 37°C under a 5% CO2 atmosphere for 24-72 h. 
5 µl of 0.02% (w/v) Resazurin (Sigma-Aldrich, R7017) in phosphate buffered saline (PBS) 
was then added to each well and incubation was continued for an additional 2 h. Finally, 
fluorescence was read using a spectramax GEMINI XS microplate reader (λexc=544 nm, 
λem=590 nm).    
Cell apoptosis detection  
Cell apoptosis was studied by using the annexin V-fluorescein isothiocyanate 
(FITC)/propidium iodide (PI) apoptosis assay kit (BD pharmingen) in combination with 
flow cytometery (CyAn ADP, Dako). After cells were pretreated with salinomycin for 12 
h, 24 h and 36 h, respectively, and with solvent control (0.1% DMSO) as well, they were 
harvested by quick trypsinization to minimize potentially high annexin V background 
levels in adherent cells. Cells were then washed twice with cold PBS and re-suspended in 
binding buffer at a concentration of 1×106 cells/ml. 100 µl cells were taken to stain with 5 
µl annexin V/FITC and 5 µl PI and incubated in dark at room temperature for 15 min. 
Then 400 µl binding buffer was added and cells were analyzed by flow cytometry. Cells 
negative for both annexin V and PI are viable, annexin V+/PI- cells are in early apoptosis, 
and annexinV+/PI+ cells are necrotic or in late apoptosis. The percentages of apoptotic cells 
were analyzed by Flowjo software. 
Cell cycle distribution analysis  
To evaluate cell cycle profile, cells (about 1×106 cells), pretreated with salinomycin for 12 
h and 24 h (0.1% DMSO as the solvent control), were harvested, washed twice with PBS, 
then fixed and stored in ice-cold 70% (v/v) ethanol at -20°C. Prior to analysis, samples 
were washed again with PBS and then incubated in propidium iodide/Rnase staining buffer 
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(BD pharmingen) at room temperature in the dark for at least 15 min. After filtration to 
remove cellular debris, the single-cell suspensions were analyzed on a flow cytometer. Cell 
cycle parameters were analyzed using Flowjo software.  
Phosphoprotein assay 
A panel of phosphoproteins was measured in duplicate using a bead-based multiplex assay 
(Bio-Plex Phosphoprotein Detection, Bio-Rad, Hercules, USA), according to the 
manufacturer’s instructions (22, 23). Briefly, cells were treated with salinomycin or with 
solvent control (0.1% DMSO) for the indicated time interval and then the cell lysates were 
collected with Bio-Plex Cell Lysis Kit. The protein concentration was measured with a DC 
(detergent compatible) protein assay (Bio-Rad) and adjusted to 600 µg/ml. Fifty 
microliters of coupled beads, which recognize phosphorylated Akt, IκB-α, ERK1/2, JNK 
and p38 MAPK, respectively, were added to the 96-well filter plate, followed by washing 
twice. Same volume of the cell lysates were added and incubated with the beads for 15–18 
h (overnight). Next, 25 µl of biotin-labelled detection antibodies were added after washing 
and incubated for 30 min. Fifty microliters of streptavidin-PE was added followed washing 
and incubated in the dark for 10 min. After rinsing, 125 µl of resuspension buffer was 
added, and the phosphoproteins were analyzed by a Bio-Plex 200 system and Bio-Plex 
Manager software (BioRad). In this assay, the lysates of Phosphotase-Treated HeLa cells, 
TNF-α-Treated Hela cells, UV-Treated HEK293 cells and EGF-Treated HEK293 cells, 
provided by the Bio-Plex phosphoprotein assay, were used as the background control and 
the positive control of phospho-IκB-α (Ser32/Ser36), phospho-p38 MAPK 
(Thr180/Tyr182), phospho-JNK (Thr183/Tyr185), phospho-Akt (Ser473) as well as 
phospho-ERK1/2 (Thr202/Tyr204, Thr185/Tyr187). This experiment was repeated in 
duplicate. 
Ovarian cancer tumor xenografts in mice 
Female mice of NOD/SCID were in-house breeding from the Animal Center 
(Tierversuchsstation) at the Department of Biomedicine, University Hospital of Basel and 
used at 6 weeks of age. All mouse procedures were approved by Cantonal Veterinary 
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Office (Kantonales Veterinäramt) and performed in accordance with the regulations 
concerning animal experiments. For in vivo salinomycin treatment study, cultured ovarian 
cancer cells (2×106 cells per mouse in 0.1 ml saline) were subcutaneously injected into the 
back of NOD/SCID mice. On the day after tumor cells injection, mice were divided into 
two groups of 5 mice each. Treatment was initiated 24 h after injection. The two 
experimental groups were administrated with salinomycin (5 mg/kg) (17) and 5% ethanol 
(vehicle), respectively, by intraperitoneal injection on every other day for 3 weeks. The 
size of the tumor was measured every 2 days using a digital vernier caliper. Tumor volume 
was estimated by the following formula: volume= (a × b2) × π/6, where a and b are major 
and minor axes of the tumor.  
Statistical analysis 
All data were expressed as mean values ± standard deviation. Growth-inhibitory curve 
were analyzed using GraphPad Prism 5.01 Software. Comparisons among groups were 
performed by Student’s t-test. The significance level was set at p<0.05. 
Results 
Growth-inhibitory effect of salinomycin on ovarian cancer cell lines  
The growth-inhibitory effect of salinomycin against OV2008, C13, A2780, A/CP, SKOV3 
and OVCAR3 cell lines is shown in Fig.1. The effect of incubation time and concentration 
on viability of the ovarian cancer cell lines by salinomycin was studied. Cells were 
exposed for 24, 48 or 72 h to salinomycin at (0.01 µM-200 µM) concentration range, and 
cell viability measured by the resazurin reduction assay. In all the six cell lines studied, the 
inhibition ratio of cell viability showed a concentration- and time-dependent pattern. IC50 
of salinomycin or cisplatin on the six ovarian cancer cell lines is reported in Table 1. This 
shows that salinomycin was slightly more potent in A2780 than in the rest of cell lines and 
was almost equipotent in the rest five cell lines, including cisplatin-resistant ovarian cancer 
cells such as C13, A/CP and SKOV3. IC50 (24 h) range of salinomycin on the six ovarian 
cancer cell lines was 1.7-7.4 µM. In addition, salinomycin was more potent in C13 cells, 
about 9-fold resistance to cisplatin, than its parent OV2008 cells (cisplatin-sensitive cells). 
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So, the C13 cisplatin-resistant human epithelial ovarian cancer cell line was attracted more 
attention and used for most parts of the study. 
Effect of salinomycin on tumor cell apoptosis and cell cycle 
Salinomycin-treated C13 cells were analyzed by flow cytometry which can distinguish 
between early apoptosis or late apoptosis of cells after cells were stained simultaneously 
with annexin V and PI. Compared to control, salinomycin treatment significantly increased 
the percentages of apoptotic cells in C13, showing a concentration- and time-dependent 
manner (Fig.2). In control culture, 4.25±0.46% cells were in early apoptosis stage whereas 
9.31±0.12% cells were in late apoptosis stage. After cells were treated with 20 µM 
salinomycin for 12 h, the percentages of apoptotic cells at early phase increased to 
16.2±0.68% and that of late phase increased to 13.7±1.17%. Whereas, when cells treated 
with salinomycin for 24 and 36 h, 25.0±0.70% and 22.1±1.91% cells were in early 
apoptosis, and 23.3±1.08% and 27.6±1.13% cells were in late apoptosis. These results 
clearly indicate that salinomycin evoked apoptosis in C13 cells. 
Effect of different concentrations of salinomycin (10 and 20 µM) on the cell cycle 
phases was investigated in C13 cells cultured over different times (12 and 24 h) by DNA 
content analysis, by flow cytometry. The results revealed that the percentages of the cell 
population in the sub-G1 phase were significantly higher in salinomycin-treated C13 cells 
with a concentration-dependent fashion, whereas the percentages of cells in other phases 
(G1/G0, S and G2/M phases) were almost reduced, in comparison with control (Fig.3). 
These effects were similar at 12 and 24 h (Fig.3). The dramatic accumulation of cells in 
sub-G1 phase was another marker for apoptosis, which further confirmed the results of 
annexin V/PI assay.  Additionally, there was no cell cycle arrest in G1/G0, S and G2/M 
phases between salinomycin-treated cells and control cells, suggesting that salinomycin 
inhibits the cellular proliferation of C13 cells not accompanied by cell cycle arrest. 
Effect of salinomycin on phosphoproteins levels in OV2008 and C13 cells 
To investigate the effect of salinomycin on phosphoproteins levels in ovarian cancer cell 
lines (OV2008 and C13), the regulation of phosphorylation by salinomycin in five proteins 
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was examined using Bio-Plex phosphoprotein assay. The results showed the basal levels of 
phosphorylation of Akt and IκB-α were higher in untreated C13 cells than in untreated 
OV2008 cells (૫1.7 fold and ૫1.6 fold, respectively) (Fig.4A, 4B). An increase in 
phosphorylation of Akt in response to salinomycin was observed in OV2008 cells (૫2.2 
fold) and C13 cells (૫1.3 fold) (Fig.4A). ERK was phosphorylated in OV2008 cells (૫2 
fold) and C13 cells (૫1.4 fold) by addition of salinomycin, but the level was independent 
of salinomycin dose and treatment time (Fig.4C). There was no clear alteration of 
phosphorylation of IκB-α (Fig.4B) and JNK (Fig.4D) after salinomycin treatment in either 
type of cell lines. But a marked concentration-dependent increase in the p38 MAPK 
phosphorylation was observed in both cell lines following salinomycin exposure for 24 h 
(Fig.4E). Phosphorylation of p38 MAPK was also enhanced by salinomycin (10 µM) after 
12, 24 and 36 h of incubation with OV2008 (Fig.4F) or C13 (Fig.4G), showing a time-
dependent fashion. These findings suggest that salinomycin-induced growth-inhibitory 
effect and apoptosis in both cell lines could be mediated through the alteration of 
phosphorylation of p38 MAPK. 
Evaluation of antitumor activity of salinomycin in vivo   
Based on the in vitro results, which showed significant cytotoxicity of salinomycin to 
human ovarian cancer cell lines, the in vivo antitumor efficacy of salinomycin was further 
evaluated in a cisplatin-resistant human ovarian tumor (C13) xenograft grown in the back 
of mice. The mice were treated with salinomycin and the change in tumor volume after 
first injection was followed for 21 days (Fig.5A). Compared with vehicle-treated controls, 
a significant reduction in the tumor volume was observed in the mice treated with 
salinomycin (Fig.5C). When the test came to the end, in C13 tumor model, the tumor 
volume of salinomycin therapy groups and controls was 84.2±30.8 mm3 and 252.5±63.4 
mm3, respectively (p<0.01; Fig.5B).   
Discussion 
In view of recent finding that salinomycin not only kills human breast cancer stem cell-like 
cells (17), but also induces apoptosis and overcomes multiple mechanisms of resistance to 
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apoptosis in human cancer cells, mainly human haematological tumor cells (18), in the 
present study we investigated the effects of salinomycin on human ovarian cancer cell 
lines, including cisplatin-resistant cell lines. As shown in Fig.1, salinomycin demonstrated 
a strong growth-inhibitory effect on ovarian cancer cell lines at a concentration- and time-
dependent manner. The six ovarian cancer cell lines were chosen for this study, including 
cisplatin-resistant cell lines such as C13, A/CP and SKOV3, which are characterised as 
advanced and refractory ovarian cancer. Salinomycin showed almost equipotent in these 
cisplatin-resistant cells, and even displayed more growth-inhibitory activity toward 
cisplatin-resistant C13 cells than its parent cisplatin-sensitive OV2008 cells (Table.1). 
These results are consistent with previous study on breast cancer cell line which indicated 
that paclitaxel-resistant cells remain sensitive to salinomycin treatment (17).   
Apoptosis, or programmed cell death, is an important homeostatic mechanism that 
balances cell division, cell death and maintains the appropriate cell number in the body 
(24). Therefore, searching for agents which trigger apoptosis of tumor cells has become an 
attractive strategy in anticancer drug discovery (25). In the present investigation, after C13 
cells were treated with salinomycin, flow cytometry results, from both annexin V/PI assay 
(Fig.2) and sub-G1 populations in cell cycle analysis (Fig.3), showed a concentration- and 
time-dependent increase in the percentage of apoptotic subpopulations. These results 
provided evidence that salinomycin triggered apoptosis in C13 cells, which resembles 
previous report on various human cancer cells such as leukemia cells (18, 19).   
Cell cycle control plays a critical role in the regulation of tumor cell proliferation. 
Many anticancer agents and DNA-damaging agents arrest the cell cycle at the G0/G1, S, or 
G2/M phase and then induce apoptotic cell death (26, 27). From the results of present 
study, it appeared that no cell cycle arrest in G1/G0, S and G2/M phases was observed 
between salinomycin-treated C13 cells and control cells (Fig. 3), which confirms previous 
finding that salinomycin activates a particular apoptotic pathway not accompanied by cell 
cycle arrest (18). 
To better understand the signal pathways involved in salinomycin-induced growth-
inhibitory effect and apoptosis in cisplatin-resistant ovarian cancer cells, we investigated 
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the activity of Akt, IκB-α, ERK1/2, JNK and p38 MAPK in cisplatin-resistant C13 cells, 
compare to cisplatin-sensitive OV2008 cells. To address this issue, multiple 
phosphoproteins were determined by Bio-Plex assays with Luminex technology. The 
recent report showed that the results achieved using Bio-Plex phosphoprotein array 
analyses significantly correlated (P<0.001) with those obtained with numerized western 
blot analyses (23). Furthermore, Bland-Altman analyses clearly demonstrated that Bio-
Plex phosphoprotein array could be used instead of western blot providing a unique way of 
analyzing multiple phosphoprotein expression in small specimens. 
The PI3-kinase/Akt pathway contributes to the tumor formation by elevating the 
activity of the anti-apoptotic action of Akt. Akt inhibits apoptosis through phosphorylation 
of Bad, GSK3, and caspase-9 and activation of transcriptional factors such as Forkhead 
(FOXO1) and NF-κB (28). It has been reported that cisplatin resistance is associated with 
the altered activation of PI3K/Akt signaling pathways in an ovarian cancer cell line (11). 
Suppression of Akt activation could lead to the activation of pro-apoptotic signaling 
pathways (29, 30). The present study showed basal levels of phospho-Akt in untreated 
cisplatin-resistant C13 cells were higher compared to cisplatin-sensitive OV2008 cells, and 
salinomycin enhanced the phospho-Akt levels in both C13 and OV2008 cells (Fig.4A). 
However, the growth inhibition effect of salinomycin on C13 cells was not significantly 
different from that of OV2008 cells. Moreover, IκB-α is a downstream Akt substrate. Via 
the phosphorylation of IκB kinase, Akt activates NF-κB, a transcription factor that has 
been implicated in cell survival (31, 32). A wealth of data has indicated that the NF-κB has 
been linked with cell proliferation, invasion, angiogenesis, metastasis, suppression of 
apoptosis and chemoresistance in multiple tumors (33). In ovarian cancer cells, it has been 
reported that increased phosphorylation of IκB-α and constitutive activation of NF-κB 
mediates cisplatin resistance and inhibition of NF-κB activation sensitizes the ovarian 
cancer cells to cisplatin (13). In the current study, basal levels of phospho-IκB-α in 
untreated cisplatin-resistant C13 cells were higher than those in untreated cisplatin-
sensitive OV2008 cells. But no phosphorylation of IκB-α was induced by salinomycin 
(Fig. 4B). These results indicate that in cisplatin-resistant C13 cells, salinomycin induces 
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apoptosis through non-Akt/IκB-α dependent pathways. The exact mechanism of the 
enhanced phospho-Akt by salinomycin is not yet know and warrants further investigation.  
MAPKs are essential parts of the signal transduction machinery and play central 
roles in cell growth, differentiation, and programmed cell death (34). Recent studies have 
suggested that apoptotic stimuli are transmitted to caspases through the activation of 
MAPKs, such as p38 MAPK and JNK (35). Therefore, we tested whether MAPK 
activation is involved in salinomycin-induced apoptosis in ovarian cancer cell lines 
(OV2008 and C13). According to our data, only p38 MAPK, and not JNK or ERK, is 
associated with the proapoptotic activity of salinomycin (Fig.4C-4G). The p38 MAPK 
pathway is implicated in cancer cell apoptosis and is induced by several chemotherapeutic 
drugs (36, 37). It was also reported that the loss of the capacity to activate p38 MAPK in 
response to cisplatin treatment may be one of the mechanisms of chemoresistance (38). We 
found there are marked time-dependent and concentration-dependent increases in the 
phosphorylation of p38 MAPK following salinomycin treatment in both cell lines (Fig.4E-
4G). This result suggests that the activation of p38 MAPK appears to contribute to the 
proapoptotic effect of salinomycin in ovarian cancer cell lines and that the activation of the 
p38 MAPK pathway might play a causal role in the salinomycin-induced apoptosis in 
ovarian cancer cell lines. However, detailed downstream and upstream signaling molecules 
of p38 MAPK modulated by salinomycin are not known and should be further 
investigated. 
In the present study, the xenografts of human cisplatin-resistant ovarian cancer 
(C13) model showed very good efficacy when treated with salinomycin (Fig.5). Although, 
we have not yet attempted to ascertain the mechanism of cell death in the xenograft tumor 
model, it is likely that cell apoptosis induced by salinomycin may account for some of the 
observed reduction in tumor growth rate and needs further investigations. Additionally, 
further studies with salinomycin alone in different characterized ovarian cancer cell lines 
or in combination with other conventional drugs in vitro and in vivo are still warranted to 
enhance our understanding of this promising antitumorigenic compound.  
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In summary, the present study demonstrated that salinomycin inhibits the growth 
and induces the apoptosis in cisplatin-resistant human ovarian cancer cell line C13 in vitro 
and exhibits significant in vivo efficacy in tumor (C13) xenograft model. The proapoptotic 
effects of salinomycin are not mediated through Akt dependent pathways, but possibly 
associated with activation of p38 MAPK and demands broader investigations to address 
the pathway involved. 
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Table 1. IC50 of cisplatin or salinomycin on ovarian cancer cell lines 
 Cisplatin  Salinomycin 
Cell lines 24 h 48 h 72 h  24 h 48 h 72 h 
OV2008        
IC50(µM) 8.08 2.49 0.60  7.44 4.78 3.20 
%95 CI 6.15 to 10.63 2.09 to 2.97 0.52 to 0.68 
 
6.80 to 8.14 4.12 to 5.55 2.90 to 3.53 
C13        
IC50(µM) 77.10 24.29 9.69  4.42 3.10 1.86 
%95 CI 65.95 to 90.13 21.85 to 27.01 8.19 to 11.46  3.62 to 5.39 2.67 to 3.59 1.67 to 2.06 
A2780 
   
 
   
IC50(µM) 6.48 1.60 1.03  1.70 0.43 0.27 
%95 CI 5.34 to 7.86 1.30 to 1.96 0.53 to 2.00  1.40 to 2.07 0.39 to 0.48 0.21 to 0.33 
A/CP        
IC50(µM) 26.09 3.35 1.84  5.56 1.02 0.51 
%95 CI 23.53 to 28.91 2.75 to 4.09 1.32 to 2.55  4.75 to 6.51 0.91 to 1.13 0.44 to 0.58 
SKOV3        
IC50(µM) 54.55 11.39 2.09  7.08 4.17 2.83 
%95 CI 38.97 to 76.35 7.17 to 18.10 1.69 to 2.59  5.33 to 9.40 3.47 to 5.01 2.14 to 3.76 
OVCAR3        
IC50(µM) 13.23 2.12 0.63  5.56 2.50 1.87 
%95 CI 10.90 to 16.06 1.83 to 2.46 0.55 to 0.72  4.30 to 7.18 2.09 to 2.98 1.32 to 2.67 
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Figure 1. Effect of salinomycin on cell viability in human ovarian cancer cell lines. Cells were exposed to 
salinomycin at concentrations (0.01-200 µM) for 24, 48 and 72 hours and cell viability measured by 
resazurin reduction assay. Results are Mean±SD of quadruplicates from one of three independent 
experiments. 
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Figure 2. Effect of salinomycin on cell apoptosis in C13 cells. After cells were treated with 10 µM or 20 
µM salinomycin for 12 h, 24 h and 36 h, respectively, and with solvent control (0.1% DMSO) as well, the 
percentage of apoptotic subpopulations was determined by flow cytometry analysis based on mean values 
obtained from three independent experiments. Results are expressed as Mean±SD. ‘*’ and ‘**’: Significant 
difference from control of time point (p<0.05 and p<0.01, respectively). ‘∆’ and ‘∆∆’: Significant difference 
from 0 h control (p<0.05 and p<0.01, respectively).  
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Figure 3. Effect of salinomycin on cell cycle distribution in C13 cells. Cells were treated with 10 µM or 20 
µM salinomycin for 12 h (A) and 24 h (B), and with 0.1% DMSO as a solvent control. The percentages of 
each cell cycle were evaluated by flow cytometry based on mean values obtained from three independent 
experiments. Results are expressed as Mean±SD. ‘*’ and ‘**’: Significant difference from control (p<0.05 
and p<0.01, respectively).  
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Figure 4. Effect of salinomycin on phosphoproteins levels in OV2008 and C13 cells. The phosphoproteins 
in OV2008 and C13 cells were assessed by the Bio-Plex assay at 24 h after different doses (1-20 µM, 0.1% 
DMSO as solvent control) of salinomycin treatment. After two washes with ice-cold cell wash buffer, 
monolayer cells were lysed. The fluorescence intensity of phosphoproteins in cells was counted by Bio-Plex 
Suspension Array System: (A) phospho-Akt; (B) phospho-IκB-α; (C) phospho-ERK1/2; (D) phospho-JNK; 
and (E) phospho-p38 MAPK. The time-dependent phospho-p38 MAPK levels in OV2008 (F) and C13 (G) 
were analyzed by the Bio-Plex assay at the indicated intervals after 10 µM salinomycin treatment (0.1% 
DMSO as solvent control). The ‘….’ line shows the signal intensity of Phosphotase-Treated HeLa cells as a 
background control. The ‘----’ line shows the signal intensity of positive control. Results are expressed as 
Mean±SD. 
PUBLISHED RESEARCH MANUSCRIPTS 
 
 
79 
 
Figure 5. Antitumor activity of salinomycin on NOD/SCID mice bearing human C13 cells. (A). Tumor-
growth curves of the mice treating with salinomycin (5 mg/kg) and vehicle control (5% Ethanol). (B). Final 
volume of tumors in salinomycin- and vehicle-treated animals on the 21th day after tumor injection. Data are 
presented as Mean±SD of tumor volumes (n=5). ‘**’: Significant difference from vehicle control (p<0.01). 
(C). One of the vehicle control group mice (up) and one of the salinomycin-treated group mice (down). 
Tumor size in salinomycin-treated mouse (down) was significantly reduced relative to tumor in vehicle-
treated mouse (up). Black bar indicates 1cm. 
 
 
PUBLISHED RESEARCH MANUSCRIPTS 
 
 
80 
References 
1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 
55: 74-108, 2005. 
2. Morrison J: Advances in the understanding and treatment of ovarian cancer. J Br 
Menopause Soc 11: 66-71, 2005. 
3. Munkarah A, Chatterjee M and Tainsky MA: Update on ovarian cancer screening. Curr 
Opin Obstet Gynecol 19: 22-26, 2007. 
4. McGuire WP, 3rd and Markman M: Primary ovarian cancer chemotherapy: current 
standards of care. Br J Cancer 89 (Suppl): S3-8, 2003. 
5. Bristow RE and Chi DS: Platinum-based neoadjuvant chemotherapy and interval surgical 
cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103: 1070-1076, 2006. 
6. Cannistra SA: Cancer of the ovary. N Engl J Med 351: 2519-2529, 2004. 
7. Kelland LR: Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs 10: 413-424, 
2005. 
8. Harries M and Gore M: Part II: chemotherapy for epithelial ovarian cancer-treatment of 
recurrent disease. Lancet Oncol 3: 537-545, 2002. 
9. Harries M and Gore M: Part I: chemotherapy for epithelial ovarian cancer-treatment at first 
diagnosis. Lancet Oncol 3: 529-536, 2002. 
10. Jansen BA, Brouwer J and Reedijk J: Glutathione induces cellular resistance against 
cationic dinuclear platinum anticancer drugs. J Inorg Biochem 89: 197-202, 2002. 
11. Lee S, Choi EJ, Jin C and Kim DH: Activation of PI3K/Akt pathway by PTEN reduction 
and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. 
Gynecol Oncol 97: 26-34, 2005. 
12. Choi KC, Auersperg N and Leung PC: Mitogen-activated protein kinases in normal and 
(pre)neoplastic ovarian surface epithelium. Reprod Biol Endocrinol 1: 71, 2003. 
13. Mabuchi S, Ohmichi M, Nishio Y, et al: Inhibition of NFkappaB increases the efficacy of 
cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 279: 23477-23485, 2004. 
14. Rudin CM, Yang Z, Schumaker LM, et al: Inhibition of glutathione synthesis reverses Bcl-
2-mediated cisplatin resistance. Cancer Res 63: 312-318, 2003. 
15. Miyazaki Y, Shibuya M, Sugawara H, Kawaguchi O and Hirsoe C: Salinomycin, a new 
polyether antibiotic. J Antibiot (Tokyo) 27: 814-821, 1974. 
PUBLISHED RESEARCH MANUSCRIPTS 
 
 
81 
16. Callaway TR, Edrington TS, Rychlik JL, et al: Ionophores: their use as ruminant growth 
promotants and impact on food safety. Curr Issues Intest Microbiol 4: 43-51, 2003. 
17. Gupta PB, Onder TT, Jiang G, et al: Identification of selective inhibitors of cancer stem 
cells by high-throughput screening. Cell 138: 645-659, 2009. 
18. Fuchs D, Heinold A, Opelz G, Daniel V and Naujokat C: Salinomycin induces apoptosis 
and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun 390: 
743-749, 2009. 
19. Fuchs D, Daniel V, Sadeghi M, Opelz G and Naujokat C: Salinomycin overcomes ABC 
transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a 
cells. Biochem Biophys Res Commun 394: 1098-1104, 2010. 
20. Riccioni R, Dupuis ML, Bernabei M, et al: The cancer stem cell selective inhibitor 
salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis 45: 86-92, 2010. 
21. Lu D, Choi MY, Yu J, Castro JE, Kipps TJ and Carson DA: Salinomycin inhibits Wnt 
signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad 
Sci U S A 108: 13253-13257, 2011. 
22. Chang L and Karin M: Mammalian MAP kinase signalling cascades. Nature 410: 37-40, 
2001. 
23. Chergui F, Chretien AS, Bouali S, et al: Validation of a phosphoprotein array assay for 
characterization of human tyrosine kinase receptor downstream signaling in breast cancer. Clin 
Chem 55: 1327-1336, 2009. 
24. Martin SJ and Green DR: Apoptosis and cancer: the failure of controls on cell death and 
cell survival. Crit Rev Oncol Hematol 18: 137-153, 1995. 
25. Reed JC: Apoptosis-targeted therapies for cancer. Cancer Cell 3: 17-22, 2003. 
26. Schwartz GK and Shah MA: Targeting the cell cycle: a new approach to cancer therapy. J 
Clin Oncol 23: 9408-9421, 2005. 
27. Vermeulen K, Van Bockstaele DR and Berneman ZN: The cell cycle: a review of 
regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36: 131-149, 2003. 
28. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J and Waterfield MD: Cellular 
function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. 
Annu Rev Cell Dev Biol 17: 615-675, 2001. 
29. Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ and Tsang BK: p53 is a determinant of 
X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer 
cells. Cancer Res 63: 7081-7088, 2003. 
PUBLISHED RESEARCH MANUSCRIPTS 
 
 
82 
30. Weir NM, Selvendiran K, Kutala VK, et al: Curcumin induces G2/M arrest and apoptosis 
in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol 
Ther 6: 178-184, 2007. 
31. Medema RH, Kops GJ, Bos JL and Burgering BM: AFX-like Forkhead transcription 
factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404: 782-787, 2000. 
32. Hayden MS and Ghosh S: Shared principles in NF-kappaB signaling. Cell 132: 344-362, 
2008. 
33. Aggarwal BB: Nuclear factor-kappaB: the enemy within. Cancer Cell 6: 203-208, 2004. 
34. Ono K and Han J: The p38 signal transduction pathway: activation and function. Cell 
Signal 12: 1-13, 2000. 
35. Park SJ and Kim IS: The role of p38 MAPK activation in auranofin-induced apoptosis of 
human promyelocytic leukaemia HL-60 cells. Br J Pharmacol 146: 506-513, 2005. 
36. Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in 
cancer development. Nat Rev Cancer 9: 537-549, 2009. 
37. Bulavin DV and Fornace AJ, Jr.: p38 MAP kinase's emerging role as a tumor suppressor. 
Adv Cancer Res 92: 95-118, 2004. 
38. Brozovic A, Fritz G, Christmann M, et al: Long-term activation of SAPK/JNK, p38 kinase 
and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug 
resistance. Int J Cancer 112: 974-985, 2004. 
 
 
SUPPLEMENTARY DATA 
 
83 
3.3 Supplementary data 
3.3.1 Supplementary data 1: p38 MAPK inhibition assay 
 
 
 
Fig.S1 Salinomycin-induced apoptosis is markedly inhibited by SB202190 (p38 MAPK inhibitor) C13 
cells were serum-starved overnight and then preincubated with or without 20 µM SB202190 for 1 h, and 
subsequently treated with 10 µM salinomycin for 24 h (0.1% DMSO as solvent control). After salinomycin 
treatments, cells were harvested and the percentages of apoptotic cells (%sub G1) were determined by flow 
cytometry. Specific apoptosis (SA) was calculated using the following formula: SA (%) =100× (AE-AC)/ 
(100-AC), where AE equals % of apoptotic cells in the experimental group and AC equals % of apoptotic cells 
in the control group. Data are given as mean values±SD.  
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3.3.2 Supplementary data 2: cell apoptosis in situ 
 
 
Fig.S2 Salinomycin induces tumor cell apoptosis in situ (A) Illustrated are representative tumor sections 
prepared from the mice treating with vehicle control or salinomycin after euthanasia. Tumor sections were 
stained with hematoxylin eosin (HE) to observe morphology (upper row) or with anti-cleaved caspase-3 
antiboday to view apoptotic cells (lower row). (B) The cleaved caspase-3 positive cells were counted to 
calculate the apoptosis index. A significant difference in apoptosis index between tumors treated with 
salinomycin versus control is denoted by “*”. White bars indicate 100µm. 
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4. SUMMARY AND OUTLOOK 
Ovarian cancer is the most frequent cause of death from gynecological cancer [201]. Even 
though there are a lot of options in treating gynecological malignancies, the therapeutic 
effect of ovarian cancer nowadays is still unfavourable, especially in treatment of the 
patients diagnosed with late stage disease [202, 203]. The development of 
chemotherapeutic drug resistance during treatment is thought to cause treatment failure and 
the high mortality rate [204, 205]. Thus, searching for alternative agents to overcome 
chemoresistance during the treatment of ovarian cancer is essential. Very recently, it has 
been shown that it is possible to selectively kill breast cancer stem cells using the 
ionophore antibiotic, salinomycin [154]. Its ability to kill cancer stem cells and apoptosis-
resistant cancer cells may define salinomycin as a novel anticancer drug [154, 155]. 
In our study, we firstly evaluated in vitro growth-inhibitory effects of salinomycin 
on six human ovarian cancer cell lines, including cisplatin-resistant cell lines such as C13, 
A/CP and SKOV3, which are characterised as advanced and refractory ovarian cancer. 
Salinomycin showed a strong growth-inhibitory effect on ovarian cancer cell lines at a 
concentration- and time-dependent manner, and even displayed more growth-inhibitory 
activity toward cisplatin-resistant C13 cells than its parent cisplatin-sensitive OV2008 cells. 
These results are consistent with previous study which indicated that drug-resistant cancer 
cells remain sensitive to salinomycin treatment [154]. Salinomycin inhibiting the growth of 
cisplatin-resistant ovarian cells suggests a possible future use of salinomycin in the 
treatment of cisplatin-resistant and aggressive ovarian cancers. 
Apoptosis, or programmed cell death, is an important homeostatic mechanism that 
balances cell division, cell death and maintains the appropriate cell number in the body 
[206]. As a regulated cell death process, apoptosis requires the cascaded activation and 
execution of a series of regulatory molecules and cysteine-aspartic proteases, known as 
caspases [207]. Stress agents, such as reactive oxygen species (ROS), ultraviolet radiation, 
viral infections, and anticancer agents are well-characterized apoptosis triggers. Recently, 
salinomycin has been reported to induce apoptosis in diverse types of apoptosis- and 
chemotherapeutic-resistant cancer cells [156]. Salinomycin-induced apoptosis has also 
SUMMARY AND OUTLOOK 
 
 
86 
been detected in various human cancer cells, such as leukemia cells [171] and prostate 
cancer cells [182]. In the present investigation, cell nuclear morphology observations by 
fluorescence microscopy and flow cytometry results, from both annexin V/PI assay and 
sub-G1 populations in cell cycle analysis, clearly provided evidence that salinomycin 
evoked apoptosis in cisplatin-resistant human ovarian cancer cell line C13 and its parent 
cisplatin-sensitive OV2008 cells. 
Cell cycle control plays a critical role in the regulation of tumor cell proliferation. 
Many anticancer agents and DNA-damaging agents arrest the cell cycle at the G0/G1, S, or 
G2/M phase and then induce apoptotic cell death [208, 209]. From the results of present 
study, it appeared that no cell cycle arrest in G1/G0, S and G2/M phases was observed 
between salinomycin-treated OV2008 or C13 cells and control cells, which confirms 
previous finding that salinomycin activates a particular apoptotic pathway not 
accompanied by cell cycle arrest [155]. However, three recent reports showed that 
treatment with salinomycin positively correlated with reduced cell cycle-related proteins, 
especially reduced p21 levels [175-177]. Salinomycin sensitized radiation-treated cancer 
cells by inducing G2 arrest [176], while it sensitized the cancer cells to antimitotic drugs 
by preventing G2 arrest [177]. 
Based on the in vitro results, which showed significant cytotoxicity of salinomycin 
to human ovarian cancer cell lines, in the present study we established human ovarian 
cancer cell lines (OV2008 or C13) xenograft tumor mouse models and further observed the 
antitumor efficacy of salinomycin in vivo. It was shown that salinomycin significantly 
inhibited the tumor growth in these both human ovarian cancer cells xenograft models. The 
preliminary analysis of tumor cell apoptosis in situ by immunohistochemistry staining of 
cleaved caspase-3 indicated that cell apoptosis induced by salinomycin might account for 
some of the observed reduction in tumor growth rate. But the mechanism of cell apoptosis 
in the xenograft tumor model is still unclear and needs further investigations.   
Identifying molecular mechanisms of anticancer action induced by salinomycin 
would be an important step in developing salinomycin-based pharmacological cancer 
therapy. A more complete understanding of the salinomycin´s anticancer mechanism could 
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facilitate the therapeutic use of salinomycin in cancer patients. In our study, Bio-Plex 
assays with Luminex technology, which is a rapid, high-throughput, multiplex, bead-based, 
quantitative assay for protein analysis, was used to investigate the effect of salinomycin on 
phosphoproteins levels in ovarian cancer cell lines (OV2008 and C13). After screening the 
activity of five proteins (Akt, IκB-α, ERK1/2, JNK and p38 MAPK), we found there are 
marked time-dependent and concentration-dependent increases in the phosphorylation of 
p38 MAPK following salinomycin treatment in both cell lines. These findings suggest that 
salinomycin-induced growth-inhibitory effect and apoptosis in both cell lines could be 
mediated through the alteration of phosphorylation of p38 MAPK. Subsequently, the link 
between p-p38 MAPK and apoptosis in salinomycin-exposed cells was also evidenced 
from the inhibition of apoptosis in SB202190 (p38 MAPK inhibitor)-pretreated OV2008 or 
C13 cells. However, detailed downstream and upstream signaling molecules of p38 MAPK 
modulated by salinomycin are not known and should be further investigated. Recently, two 
reports [182, 183] indicate that salinomycin inhibits prostate cancer cell growth via 
induction of oxidative stress. Reactive oxygen species (ROS) are implicated as important 
mediators of apoptotic cell death. MAPK is considered as one of the most important 
signaling molecules in ROS-mediated apoptosis in cancer cells [210, 211]. Oxidative stress 
has also been reported to play a role in p38 MAPK activation [211]. Our findings show a 
significant increase in the phosphorylation of p38 MAPK following salinomycin treatment 
in both cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Although, 
we have not yet attempted to measure intracellular ROS induced by salinomycin in our cell 
lines, it remains possible that ROS trigger is an upstream signal which may contribute to 
the enhanced p38 MAPK activity and initiate the series of apoptotic events induced by 
salinomycin, which is warranted further investigations. 
In order to better enhance our understanding of the effect of salinomycin, this 
promising antitumorigenic compound, on human ovarian cancer cells, the future research 
will focus on three main aspects: One is further in vitro and in vivo studies with 
salinomycin alone in different characterized ovarian cancer cell lines, such as p53 
mutation/null cell lines, various drug-resistant cell lines or patient-derived primary ovarian 
cancer cells, and investigating its mechanism of action as well. Another is evaluating 
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whether salinomycin could selectively target cancer stem cells in ovarian cancer. The third 
is research on salinomycin in combination with other conventional drugs in vitro and in 
vivo to improve the efficiency of therapy in ovarian cancer. 
Due to the severe neural and muscular toxicity of salinomycin observed in 
mammals, including human beings [193, 194, 198, 199], its use as a feed additive is no 
longer authorized in the European Union and United States [190]. The considerable 
toxicity is also one important obstacle for the potential clinical use of salinomycin. 
Searching for a new group of salinomycin derivatives which will be more effective in 
coordination of biologically important metal cations and less toxic especially for humans 
will be a challenge for the coming years. Moreover, future studies with salinomycin in 
humans should be designed carefully. 
In conclusion, this work demonstrated that salinomycin is a potent compound 
against cisplatin-resistant human ovarian cancer cell line C13 and its parent cisplatin-
sensitive OV2008 cells in vitro and in vivo. Salinomycin can inhibit the growth of both cell 
lines efficiently through induction of apoptosis, which is not accompanied by cell cycle 
arrest, but possibly is associated with activating p38 MAPK and merits further 
investigations. Salinomycin shows substantial promise for further development as a 
potential agent for treating ovarian cancer, especially drug-resistant ovarian cancer. 
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